question booklet specific paperkpsc.kar.nic.in/27.pdf · 27 (3 – a) 1. in a polarimeter a...

INSTRUCTIONS

1. Immediately after the commencement of the Examination, before writing the Question

Booklet Version Code in the OMR sheet, you should check that this Question Booklet

does NOT have any unprinted or torn or missing pages or questions etc. If so, get it

replaced by a complete ‘Question Booklet’ of the available series.

2. Write and encode clearly the Register Number and Question Booklet Version Code

A, B, C or D as the case may be, in the appropriate space provided for that purpose

in the OMR Answer Sheet. Also ensure that candidate’s signature and Invigilator’s

signature columns are properly filled in. Please note that it is candidate’s

responsibility to fill in and encode these particulars and any omission/discrepancy

will render the OMR Answer Sheet liable for Rejection.

3. You have to enter your Register Number in the

Question Booklet in the box provided alongside.

DO NOT write anything else on the Question Booklet.

4. This Question Booklet contains 100 questions. Each question contains four responses

(choices/options). Select the answer which you want to mark on the Answer Sheet.

In case you feel that there is more than one correct response, mark the response which

you consider the most appropriate. In any case, choose ONLY ONE RESPONSE for each

question.

5. All the responses should be marked ONLY on the separate OMR Answer Sheet provided

and ONLY in Black or Blue Ballpoint Pen. See instructions in the OMR Answer Sheet.

6. All questions carry equal marks. Attempt all questions.

7. Sheets for rough work are appended in the Question Booklet at the end. You should not

make any marking on any other part of the Question Booklet.

8. Immediately after the final bell indicating the conclusion of the examination, stop

making any further markings in the Answer Sheet. Be seated till the Answer Sheets are

collected and accounted for by the Invigilator.

9. Questions are printed both in English and Kannada. If any confusion arises in the

Kannada Version, refer to the English Version of the questions. Please Note that in

case of any confusion the English Version of the Question Booklet is final.

µåÔåêÅÜÝ ‘ ÜÈåëôåÄð µåâÿå ’åÄåÆ µå „Ôåï½¾²ìåêê † ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð²ìåê àÒÊ·æ µåÁµåÑ–Ó ÔåêêÁ™ÐÜÈåÑÉ°±Áµð.

DO NOT OPEN THIS QUESTION BOOKLET UNTIL YOU ARE ASKED TO DO SO

Time Allowed : 2 Hours Maximum Marks : 200

Version Code

QUESTION BOOKLET

SPECIFIC PAPER

(PAPER-II)

A

SUBJECT CODE : 27 Serial No. :

Use of Mobile Phones, Calculators and other Electronic/Communicationgadgets of any kind is prohibited inside the Examination venue.

Register Number

27-A

27 (2 – A)

1. ÇÈðîÑæ²™Õêé®²µóÄåÑ–Ó, ÁµåêÏ½é²ìåêÔæ˜™

“Ð²ìåìæØéÑÔæÁµå ÜÈåÒ²ìåêê’å¾Áµå ÁµæÐÔå ÔåÄåêÆ

† ’ðâÿå’åÒ´µåÔåíú˜µåâÿå Äå µåêÕÄå Êðâÿå“Äå

ÇÈåÁ¿·µåÁµåÑ–Ó …²™ÜÈåÑæ˜µåê¼å¾Áµð.

(a) ‡¼å¾²µåÁ·µåêÐÔå Ôåê¼åê¾ Áµå“Û¸ Á·µåêÐÔå

(b) Õ“²µå Áµå ÔåêëÑ Ôåê¼åê¾ ÔåêÜÈåë²µå

(c) Á·µåêÐÕé’æ²µå’å Ôåê¼åê¾ ƒÄåÑðñÜÈå²µó

(d) ’æÑ–ÓÔðêé®²µó Ôåê¼åê¾ Õ“²µå Áµå

ÔåêëÑ

2. ²µðé•–é²ìåêÔæ˜™ ÁµåêÐÕé’åï¼åÔæÁµå Êðâÿå’åê

’ðâÿå’åÒ µåÁµåÂ²µðëÒÁ™˜µð ‡¼æÉÁ™¼åÔæ˜µåê¼å¾Áµð.

(a) ’åÛ-“²µå

(b) Á·µåêÐÕé’å²µå¸

(c) ’ðëÐÔåìæ ðëé˜µæÐÇ·Ý ¼åÒ¼åÐ

(d) ÇÈå²µåÔåìæ¸êÕÄå ÇÈå²™Ê·åùÐÔåê¸Áµå

ÔåêëÑ’å

3. ÇÈðîÑæ²™Õêé®²µåÄåÑ–Ó ÊâÿåÜÈåÑæ˜µåêÔå

Á·µåêÐÕé’æ²µå’å ²ìåìæÔåíúÁµåê ?

(a) Å’ðëéÑó ÇÝÐÜÈåÒ

(b) ÔåìæÏ˜µðÆ°’ó ÇÈðîéÑó

(c) Õ“²µå Áµå ÔåêëÑ

(d) ¼æÔåêÐÁµå ¼åÒ½

4. ¼å²µåÒ µåÁµåë²µåÁµðëÒÁ™˜µð ÜÈðÉÜÝÇ·Ý’ó

²µðë ðé×åÅÆÄå ÊÁµåÑæÔå¹ð²ìåê Áµå²µåÔåÄåêÆ

àé˜µð ’å²µð²ìåêê¼æ¾²µð.

(a) „ÇÝ±’åÑó ²µðë ðé®²™ ´™ÜÈóÇÈå×å¤Äó

(b) Ôå¼åê¤Ñæ’æ²µåÁµå ´µðñ’ðëÐéÎêÜÈåÒ

(c) ƒÊæÞÇÈå¤×åÄó ÔåìæÏ“ÞÔåìæ

(d) ’ðëÐéÔðëéÇ·Èðùîé²µó

5. ¼å²µåÒ µå Áµåë²µåÁµðëÒÁ™ µð Á™é›å¤Ôåï½¾é²ìåê¼ð-

²ìåê ÔåìæÇÈæ¤ µåÄåêÆ Áµæ•Ñ–ÜÈåêÔåíúÁµåê

(a) ƒÊóÜÈæÇÈå¤×åÄó ÜÈðÉ’æ±ø

(b) ÔåìæÑ–’åëÏÑ²µó ÜÈðÉ’æ±ø

(c) ÜÈå’åêÏ¤Ñ²µó µðñ’ðëÐéÎêÜÈåÒ ÜÈðÉ’æ±ø

(d) ORD ÜÈðÉ’æ±ø

6. ÁµåêÏ½é²ìåêÔæ˜™ “Ð²ìåìæØéÑÔæÁµå

ÇÈåÁµæÁ¿·µå¤Ôåíú ’ðâÿå’åÒ µå ÜÈæÔåêÁ¿·µåùÏ¤ ßðëÒÁ™Áµð

ŠÄåÆÑæ˜µåê¼å¾Áµð.

(a) Á·µåêïÕé’åï¼å Êðâÿå“Äå ÜÈåÔåê¼åÑÔåÄåêÆ

½²µåê˜™ÜÈåêÔå ÜÈæÔåêÁ¿·µåùÏ¤

(b) ŠÑð’æ±øÅ’ó ÜÈåÒ’åÐÔåê¸˜µåâÿåÄåêÆ

ßðëÒÁ™²µåê¼å¾Áµð

(c) ÇÈå²µåÔåìæ¸ê µåâÿå ’åÒÇÈåÄå µåâÿåÄåêÆ

ÊÁµåÑæÎêÜÈåêÔåíúÁµåê

(d) ÄåëÏ“Ó²ìåêÜÈóÄå ÇÈå²™Ê·åùÐÔåê¸ÔåÄåêÆ

ÔåÏ¼æÏÜÈå µðëâ–ÜÈåêÔåíúÁµåê

27 (3 – A)

1. In a polarimeter a solution of an

optically active compound is

placed in the light path between

(a) North pole and South pole

(b) Radiation source and lens

(c) Polariser and Analyser

(d) Collimator and radiation

source

2. Linearly polarized light is

produced with a

(a) X-ray

(b) Polariser

(c) Chromatography technique

(d) Spinning of the atom

3. Polariser used in the polarimeter

is

(a) Nicole prism

(b) Magnetic pole

(c) Radiation source

(d) Copper wire

4. Rate of change of specific

rotation with wavelength is

known as

(a) Optical rotatory dispersion

(b) Circular dichroism

(c) Absorption maxima

(d) Chromophore

5. Recording the variation of

ellipticity with wavelength is

(a) Absorption spectra

(b) Molecular spectra

(c) Circular dichroism spectra

(d) ORD spectra

6. Optically active substance is said

to be

(a) capable of rotating the plane

of polarized light.

(b) having the electronic

transitions.

(c) changing the vibrations in

atoms.

(d) varying the spin of the

nucleus.

27 (4 – A)

7. ƒ’ð±Ò¯ó Å²ìåêÔåêÔåíú ²ìåìæÔåíúÁµå’ð”

ƒÄåÖÎêÜÈåê¼å¾Áµð ?

(a) ÇÈåÐ½ÜÈæÀÇÝ¼åÔæÁµå „Ñó’ðéÄó˜µåâ–˜µð

(b) ÇÈåÐ½ÜÈæÀÇÝ¼åÔæÁµå „Ñ–”éÄó˜µåâ–˜µð

(c) ÇÈåÐ½ÜÈæÀÇÝ¼åÔæÁµå ÜÈðÏ’ðëÓßð’æÞÄðëéÄó

˜µåâ–˜µð

(d) ÇÈåÐ½ÜÈæÀÇÝ¼åÔæÁµå ÊðÄó¨éÄó˜µåâ– µð

8. ’ðâÿå ™Äå ÇÈå°±²ìåêÑ–Ó ²ìåìæÔå Á·µæ¼åêÔåíú NMR

ÄðëÒÁ™ µð ÇÈåÐ½ÜÈåÉÒÁ™ÜÈåêÔåíúÁ™ÑÓ ?

(a) 13C

(b) 12C

(c) 17O

(d) 1H

9. ’ðâÿå ™Äå ²ìåìæÔå §ÒÁµåê ¼å¼åÖÁµå ÔðêéÑð NMR

’ðÑÜÈå Ôåìæ´µåê¼å¾Áµð ?

(a) ’æÒ½é²ìåê ’ðÛé¼åÐÁµåÑ–Ó, §ÒÁµåê

ÔåìæÁµå²™²ìåêê ²µðé´™²ìðëé

„Ôå¼æ¤Ò’åÔåÄåêÆ àé²µåê¼å¾Áµð

(b) UV Õ“²µå ÔåÄåêÆ àé²™’ðëâÿåêä¼å¾Áµð

(c) ÊÒÊæ´µó¤ÔðêÒ¯ó ÔåêëÑ’å

ƒ²ìåìæÄåê˜µåâÿåÄåêÆ ²µå¡ÜÈåê¼å¾Áµð

(d) UV Ôåê¼åê¾ IR Õ“²µå ˜µåâÿåÄåêÆ

àé²™’ðëâÿåêä¼å¾Áµð

10. † ’ðâÿå˜™ÄåÔåíú˜µåâÿåÑ–Ó NMR ØÇ·Èó± ²™‹¦ÿðÒ¯ó

˜µåâÿåÄåêÆ „²™ÜÝ.

(a) TMS ˜µåâÿå ¡éÑðé¯ó˜µåâÿåê

(b) EDTA ²ìåê ¡éÑðé¯ó˜µåâÿåê

(c) ²ìåêê²µðëéÇÝ²ìåêÒÄå ƒÄåê’æÒ½é²ìåê

¡éÑðé¯ó˜µåâÿåê

(d) CDCl3

11. ÇÈå²µåÔåìæ¸ê µåâÿå ÄåëÏ“Ó²ìðê²ìåìó ²ìåêÄåêÆ

„Á·µå²™ÜÝÁµå ÜÈðÉ’ðë±øéÜÈðë”éÇÝ ²ìåìæÔåíúÁµåê ?

(a) UV ÜÈðÉ’ðë±øéÜÈðë”éÇÝ

(b) FTIR ÜÈðÉ’ðë±øéÜÈðë”éÇÝ

(c) NMR ÜÈðÉ’ðë±øéÜÈðë”éÇÝ

(d) Visible ÜÈðÉ’ðë±øéÜÈðë”éÇÝ

12. ’æÖÒ®Ò ÜÝÉÄó ÜÈåÒ•ÿðÏ (l) ²ìåìæÔåíúÁµå’ð”

ÜÈåÒÊÒÁ·™ÜÝÁµð ?

(a) ŠÑð’æ±øÄåê˜µåâÿå ÜÈåÒ•ÿðÏ

(b) ÇÈå²µåÔåìæ¸êÕÄå ÜÈåÒ•ÿðÏ

(c) ÇÈå²µåÔåìæ¸êÕÄå ÁµåÐÔåÏ²µæØ

(d) ÇÈå²µåÔåìæ¸êÕÄå ÁµåÐÔåÏ²µæØ Ôåê¼åê¾

ÇÈå²µåÔåìæ¸êÕÄå ÜÈåÒ•ÿðÏ

27 (5 – A)

7. Octant rule is applicable for

(a) Substituted alkanes

(b) Substituted alkenes

(c) Substituted cyclohexanones

(d) Substituted benzenes

8. In the following list which

element does not responds to

NMR ?

(a) 13C

(b) 12C

(c) 17O

(d) 1H

9. NMR works on one of the

principle :

(a) In a magnetic field, a sample

absorb radio frequency.

(b) Absorbs the UV radiation.

(c) Formation of ions by

bombardment.

(d) Absorbs UV and IR

radiations.

10. Pick the NMR shift reagents from

the following :

(a) Chelates of TMS

(b) Chelates of EDTA

(c) Paramagnetic chelates of

europium

(d) CDCl3

11. The spectroscopy based on the

nuclei of atoms is

(a) UV spectroscopy

(b) FTIR spectroscopy

(c) NMR spectroscopy

(d) Visible spectroscopy

12. Quantum spin number (l) is

associated with

(a) Number of electrons

(b) Atomic number

(c) Atomic mass

(d) Atomic mass and Atomic

number

27 (6 – A)

13. ’æÒ½é²ìåê ÇÈðÐé²µå¹ð²ìåêÄåêÆ (B) ²ìåìæÔå

‹’åÔåìæÄå˜µåâÿåÑ–Ó ƒâÿð²ìåêê¼æ¾²µð ?

(a) Ôðê˜µæ ßå¯ó©¤

(b) ðÜÈæÓ

(c) Cm

(d) nm

14. ÊðÄó¦ÿðñÑó „Ñðë”éßæÑóÄå ÇÈðîÐ¯æÄó

NMR ÜÈðÉ’å±øÒÄåÑ–Ó ŠÚÈåê± ×åïÒ˜µå µåâ–²µåê¼å¾Ôð ?

(a) ’ðéÔåÑ §ÒÁµåê ×åïÒ˜µå

(b) Š²µå µåê ×åïÒ˜µå µåâÿåê

(c) Ôåêë²µåê ×åïÒ µå µåâÿåê

(d) §ÒÊ¼åê¾ ×åïÒ˜µå µåâÿåê

15. ²µæÜÈæ²ìåêÅ’å ØÇ·Èó± ÜÈæÀÄå µåâÿåÄåêÆ ÜÈæÔåìæÄåÏ-

Ôæ˜™ ’ðâÿå’åÒ µåÒ¼ð ÔåÏ’å¾ÇÈå ™ÜÈåÑæ˜µåê¼å¾Áµð.

(a) δ (´µðÑæ±)

(b) β (Ê–é¯æ)

(c) γ (˜µæÔåìæ)

(d) α („ÑæÉÃ)

16. NMR ÜÈðÉ’æ±øÁµåÑ–Ó ÊâÿåÜÈåêÔå ÁµæÐÔå’å

²ìåìæÔåíúÁµåê ?

(a) CDCl3

(b) CH3OH

(c) HCHO

(d) CH3COCH3

17. † ’ðâÿå ™Äå ÇÈå°±ÎêÒÁµå NMR Äå ƒ¼åÏÁ·™’å δ

ÔåìòÑÏ˜µåâÿåÄåêÆ „²ìðê” Ôåìæ´™.

(a) CH3I

(b) CH3Br

(c) CH3Cl

(d) CH3F

18. ÁµåÐÔåÏ²µæØ ²µðëéà¼åÔåíú (Mass Spectrum) †

’ðâÿå’åÒ µåÁµå²µå ÇÈæÓ¯ó „ ™Áµð.

(a) àé²µåêÕ’ð µð ÇÈåÐ½²ìåìæ˜™ ÜÈæÒÁ™Ðé

’å²µå¸

(b) m/z ƒÄåêÇÈæ¼å’ð” ÇÈåÐ½²ìåìæ˜™

ƒ²ìåìæÄó ÜÈåÔåêïÁµåÂÃ¼ð

(c) ÇÈðÐéÚÝ¼å¼åÖ’ð” ÇÈåÐ½²ìåìæ˜™ ¼å²µåÒ µå

ÜÈåÒ•ÿðÏ

(d) ÁµåêÏ½é²ìåê ÜÈæÒÁµåÐ¼ð˜µð ÇÈåÐ½²ìåìæ˜™

¼å²µåÒ µå Áµåë²µå

27 (7 – A)

13. Magnetic induction(B) measuring

unit

(a) Mega hertz

(b) Tesla

(c) Cm

(d) nm

14. How many peaks will be present

in the proton NMR spectrum of

benzyl alcohol ?

(a) Only one peak

(b) Two peaks

(c) Three peaks

(d) Nine peaks

15. Chemical shift positions are

normally expressed in

(a) δ (Delta)

(b) β (Beta)

(c) γ (Gama)

(d) α (Alpha)

16. Solvent used in the NMR spectra :

(a) CDCl3

(b) CH3OH

(c) HCHO

(d) CH3COCH3

17. Pick the highest δ value of NMR

in the following :

(a) CH3I

(b) CH3Br

(c) CH3Cl

(d) CH3F

18. The mass spectrum is the plot of

(a) Concentration versus

absorbance

(b) Ion abundance versus m/z

ratio.

(c) Wave number versus

transmittance.

(d) Wavelength versus optical

density.

27 (8 – A)

19. ¯æÏÄå´µðÔåìó ÁµåÐÔåÏ²µæØ ÜÈðÉ’ðë±øéÔðê°Ð²ìåêÄåêÆ àé˜µåë ½â–²ìåêÑæ˜µåê¼å¾Áµð ?

(a) MS/MS

(b) MS

(c) ²µæÜÈæ²ìåêÅ’å ƒ²ìåìæÅé’å²µå ¼åÒ¼åÐÁµðëÒÁ™˜µð MS

(d) ESI ¼åÒ¼åÐÁµðëÒÁ™ µð MS

20. MALDI Äå ÕÜÈå¾üï¼å²µåëÇÈå

(a) Mass Acquiring Longer

Desorption Ion.

(b) Mass Assisted Layer De-

Ionisation.

(c) Matrix Assisted Laser

Desorption-Ionisation.

(d) Mass Acquired Lower

Deformation Ion.

21. ÁµåÐÔåÏ²µæØ ÜÈðÉ’ðë±øéÔðê°Ð²ìåêê …¼å²µå ÜÈæÔåìæÄåÏ ÜÈðÉ’å±øÑó Õ×ðÓéÚÈå¹æ ÇÈåÐ’æ²µå µåâ–ÒÁµå ’ðâÿå’åÒ µå ²™é½²ìåêÑ–Ó Ê–·ÄåÆÔæ˜™Áµð.

(a) ÕÁµåêÏ¼ó ’æÒ½é²ìåê Õ“²µå¸ ÜÈðÉ’å±øÔåìó Äå ‡¼åÞ¨¤ÜÈåêÕ’ð

(b) UV Õ“²µå ÔåÄåêÆ àé²™’ðëâÿåêäÔåíúÁµåê

(c) ²µðé´™²ìðëé ¼å²µåÒ˜µå˜µåâÿåÄåêÆ àé²™’ðëâÿåêäÔåíúÁµåê

(d) ÕÁµåêÏ¼ó ’æÒ½é²ìåê ÜÈðÉ’å±øÔåìó ÅÒÁµå IR, UV ÁµåÒ¼åßå Õ“²µå ÔåÄåêÆ ƒÁ¿·µåÔæ ²µðé´™²ìðëé ¼å²µåÒ˜µå˜µåâÿåÄåêÆ àé²™’ðëâÿåêäÔåíúÁ™ÑÓ

22. ƒ²ìåìæÅé’å²µå Áµå ’ðëé¹ð²ìåêÑ–Ó ²µåëÇÝ¼åÔæÁµå ƒ½ ÜÈåÔåêïÁµåÂÃÔæÁµå ƒ²ìåìæÄåê, ÁµåÐÔåÏ²µæØ ²µðëéà¼åÁµåÑ–Ó † ’ðâÿå’åÒ´µåÒ¼ð ’å²µð²ìåêÑæ˜µåêÔå ƒ½ Š¼å¾²µåÔæÁµå ×åïÒ µåÁµå ßåê°±˜µð Š´µðÔåìæ ™’ðë´µåê¼å¾Áµð.

(a) ÔåìæÑ–’åêÏÑæ²µó ƒ²ìåìæÄó ×åïÒ˜µå

(b) ƒ¯æÕê’ó ×åïÒ˜µå

(c) ÔåìæÑ–’åëÏÑó ×åïÒ˜µå

(d) ÊðéÜÈó ×åïÒ µå

23. PFTBA [perfluoro tri-n-ÊêÏ ðñÑó

ƒÔðêñÄó – (CF3CF2CF2CF2)3N]

(a) ÁµåÐÔåÏ²µæØ ÜÈðÉ’ðë±øéÔåìæÇÈå’å˜µåâÿå ®ëÏÅÒ˜µó ßæ˜µåë ’æÏÑ–ÊðÐé×åÄåÄåÑ–Ó ÊâÿåÜÈåÑæ˜µåê¼å¾Áµð

(b) NMR ÄåÑ–Ó²µåêÔå ²µðÇ·Èå²µðÄóÞ

(c) ÄðÇ·ÈðÑðëéÔðê°Ð ßæ˜µåë ®Ê–¤ µðëé Ôðê°Ð²ìåêÑ–Ó ÊâÿåÜÈåÑæ˜µåêÔå ÜÈæ±ûÏÒ´µå µó¤

(d) Ç·ÈåùîúÓ²µðëéÜÈðÒ¯ó …Ò ™’ðé®²µó

24. 2-ÕêéÁ¿·µðñÑó ÇÈðÒ ðéÄó Äå ÁµåÐÔåÏ²µæØ ²µðëéà¼åÔåíú † ’ðâÿå˜™ÄåÁµå²µåÑ–Ó ÔåìæÑ–’åêÏÑ²µó ƒ²ìåìæÄó ×åïÒ˜µåÔåÄåêÆ ¼ðëé²™ÜÈåê¼å¾Áµð.

(a) 43

(b) 57

(c) 71

(d) 86

27 (9 – A)

19. Tandem mass spectrometry also

known as

(a) MS/MS

(b) MS

(c) MS with chemical ionization

technique

(d) MS with ESI technique

20. MALDI is

(a) Mass Acquiring Longer

Desorption Ion.

(b) Mass Assisted Layer De-

Ionisation.

(c) Matrix Assisted Laser

Desorption-Ionisation.

(d) Mass Acquired Lower

Deformation Ion.

21. Mass spectrometry differs from

other common forms of spectral

analysis in the following way :

(a) Emitting Electromagnetic

radiation spectrum.

(b) Absorbing UV radiation.

(c) Absorbing Radio Waves.

(d) Does not absorb radiation

such as IR, UV or Radio

Waves from the

electromagnetic spectrum.

22. The most abundant ion formed in

the ionization chamber gives rise

to the tallest peak in the mass

spectrum called as

(a) Molecular ion peak

(b) Atomic peak

(c) Molecule peak

(d) Base peak

23. PFTBA [perfluoro tri-n-butyl

amine – (CF3CF2CF2CF2)3N]

(a) Used for tuning and

calibration of mass

spectrometers.

(b) Reference in NMR

(c) Standard used in

Nephelometry and

Turbidometry.

(d) Fluorescent indicator.

24. Mass spectrum of 2-methyl-

pentane shows the Molecular ion

peak at

(a) 43

(b) 57

(c) 71

(d) 86

27 (10 – A)

25. ²™ÔåÜÈó¤ Ç·Èðé¦ÿó HPLC ²ìåêÑ–Ó ÜÈð±é×åÄå²™ Ç·Èðé¦ÿó ’ðâÿå’åÒ µåÒ½²µåê¼å¾Áµð.

(a) Á·µåêÐÕé²ìåê

(b) Á·µåêÐÕé²ìåê ÔåÑÓÁµå

(c) ²µðé´™²ìðëé ŒÜÈðëé ðëéÇÈó ˜µåâÿåê

(d) ÊðéÜÝ’ó

26. HPLC ÕÁ·µæÄåÔåÄåêÆ ²ìåìæÔåíúÁµå’ð” ÊâÿåÜÈåê¼æ¾²µð ?

(a) ÜÈåÒ²ìåêê’å¾Áµå Ôåê¼åê¾ ÜÈåÒ²ìåêê’å¾Áµå ÇÈåïÁ¿·µå’å”²µå¸ (ÊðéÇÈå¤´™ÜÈåêÕ’ð²ìåê) ÇÈå²™Ôåìæ¹æ¼åÍ’å ƒÒÁµæ¨˜µð

(b) ÔåìæÑ–’åëÏÑóÄåÑ–Ó²µåêÔå ŠÑð’æ±øÄåê ˜µåâÿåÄåêÆ ˜µåê²µåê½ÜÈåêÔåíúÁµå’ð”

(c) ÜÈåÒ²ìåêê’å¾Áµå “Ð²ìåìæØéÑ ˜µåêÒÇÈåÄåêÆ ˜µåê²µåê½ÜÈåêÔåíúÁµå’ð”

(d) ÜÈåÒ²ìåêê’å¾Áµå ÁµåÐÔåÏ²µæØ²ìåêÄåêÆ ÅÁ·µå¤²™ÜÈåêÔåíúÁµå’ð”

27. HPLC ²ìåêÑ–Ó µæ´µó¤ ’æÑÒÄåêÆ ÊâÿåÜÈåêÔå ‡ÁµðÂé×åÔðéÄåê ?

(a) Õê×åÐ¸ÔåÄåêÆ ¼åÖ²™¼åÔæ˜™ ÇÈåÐ¼ðÏé“ÜÈåêÔåíúÁµåê

(b) ƒÄåÑ–°’åÑó ’æÑÒÄå ¨éÔæÔåÁ·™ ²ìåêÄåêÆ Á™é›å¤˜µðëâ–ÜÈåêÔåíúÁµåê

(c) ÜÈåÒ²ìåêê’å¾ µåâÿåÄåêÆ ÇÈåÐ¼ðÏé“ÜÈåêÔåíúÁµåê

(d) ÇÈå²™Ôåìæ¹æ¼åÍ’å ƒÒÁµæ¦ê Ôåìæ´µåêÔåíúÁµåê

28. HPLC ²ìåêÑ–Ó ÊâÿåÜÈåÑæ˜µåêÔå ×ðëéÁ·µå’å

(a) ¦ÿæÖÑæ ƒ²ìåìæÅé’å²µå Áµå ×ðëéÁ·µå’å

(b) ’åÛ-“²µå ’ðëâÿåÔð

(c) ÇÈðîÑæ²™ ÔåìæÇÈå’å

(d) ´µå²ìðëé´µó ƒ²µðé ×ðëéÁ·µå’å

29. ODS ÜÝÑ–’æ ¦ÿðÑó ’æÑÒ˜µåâÿåÄåêÆ àé˜µåë

’å²µð²ìåêê¼æ¾²µð

(a) C4 ’æÑÒ

(b) C8 ’æÑÒ

(c) C18 ’æÑÒ

(d) C20 ’æÑÒ

30. Á·µæ²µå¸ ÜÈæÔåêÁ¿·µåùÏ¤ ÜÈåÔåê²ìåêÔåÄåêÆ àé˜µð

ÔæÏ•ÿæÏÅÜÈåÑæ˜µåê¼å¾Áµð.

(a) ÇÈæÐ²µåÒÊ–·ÜÈåêÔå ÜÈåÔåê²ìåê

(b) …Ò¦ÿð’åÛÅÆÄå ÄåÒ¼å²µå, §ÒÁµåê ›å®’åÁµå

×åïÒ˜µå ÔåìæÏ“ÞÔåìæÔåíú ‡¼åÞ¦¤Äð

²ìåìæ˜µåêÔå ÜÈåÔåê²ìåê

(c) ƒÒ¼åÏÔæ˜µåêÔå ÜÈåÔåê²ìåê

(d) ÔåìæÁµå²™²ìåêÄåêÆ …Ò¦ÿð’ó± Ôåìæ´™Áµå

ÜÈåÔåê²ìåê

27 (11 – A)

25. In Reverse Phase HPLC the

stationary phase is

(a) Polar

(b) Non-polar

(c) Radio isotopes

(d) Basic

26. HPLC method is applied for the

(a) Quantitative estimation of

the compound and Isolation

of compound.

(b) Identification of electrons

present in molecule.

(c) Identifying the functional

groups of the compound.

(d) Determination of the mass of

the compound.

27. Use of Guard Column in the

HPLC is

(a) To separate the mixture

fastly.

(b) To prolong the life of

analytical column.

(c) To separate compounds.

(d) For the quantitative estimation.

28. The detector used in the HPLC.

(a) Flame ionization detector

(b) X-ray tube

(c) Polarimeter

(d) Diode array detector

29. ODS silica gel columns are also

called as

(a) C4 column

(b) C8 column

(c) C18 column

(d) C20 column

30. Retention time is defined as

(a) Starting time.

(b) Time of emergence of the

peak maxima of a

component after injection.

(c) Ending time.

(d) Sample injected time.

27 (12 – A)

31. ÊæÎê²ìåê Ñðëéâÿð ÇÈåÁµæÁ¿·µå¤Áµå ÇÈæ²µå µåÔåêÏ¼ð²ìåêê ’ðâÿå’åÒ´µå ’åÐÔåêÁµåÑ–Ó ’å ™Ôðê²ìåìæ˜µåê¼æ¾ ßðëé µåê¼å¾Áµð.

(a) ÜÈåÊóÑ–Ò µåêÏ²ìåêÑó, ÊëÏ’åÑó Ôåê¼åê¾ ÇÈåÏÑð®Ñó

(b) ÊëÏ’åÑó, ÜÈåÊóÑ–Ò µåêÏ²ìåêÑó Ôåê¼åê¾ ÇÈåÏÑð®Ñó

(c) ÇÈåÏÑð®Ñó, ÊëÏ’åÑó Ôåê¼åê¾ ÜÈåÊó Ñ–Ò˜µåêÏ²ìåêÑó

(d) ÊëÏ’åÑó, ÇÈåÏÑð®Ñó Ôåê¼åê¾ ÜÈåÊó Ñ–Ò˜µåêÏ²ìåêÑó

32. ×åêÚÈå” ’åº»Äå ÜÝÒ´µðëÐéÕêÄå ¡“¼ðÞ²ìåêÑ–Ó ÊâÿåÜÈåÑæ˜µåêÔå ßðñ µæÐ“ÞÇÈðîÐÇÈðñÑó ÜÈðÑêÏ-ÑðëéÜÈóÅÒÁµå Ôåìæ ™Áµå ÜÈð±²µðñÑó ÜÈå²µåâ–Äæ’æ²µåÁµå ÜÈæÁ·µåÄå ²ìåìæÔåíúÁµåê ?

(a) SODI

(b) ÕêÅ´™ÜÈó”

(c) OTS

(d) ÑæÏ“ÐÜÈå¯ó¤

33. ËÚÈåÁµå ×æÜÝ¾øé²ìåê ÅÔåìæ¤¸Áµå ÔðêéÑðÍþñ²µåëÇÈå ²µåôåÄð²ìåêÄåêÆ, ’ðâÿå’åÒ µåÁµåÂÄåêÆ ÊâÿåÜÝ ÇÈå²™ØéÑÄð Ôåìæ´µåÊßåêÁµåê.

(a) UV ÜÈðÉ’ðë±øéÜÈðë”éÇÝ

(b) ÜÈæ”þÏÅÒ µó ŠÑð’æ±øÄó Ôðêñ’ðëÐé ÜÈðë”éÇÝ

(c) FTIR ÜÈðÉ’ðë±øéÇ·Èðùîé ðëéÕêé®²µó

(d) ´™Ç·Èå²µðÅÙ²ìåêÑó ÜÈæ”þÏÅÒ˜µó ’åÑðëé²™Ôðê°Ð

34. SODI ŠÒÊ ËÚÈåÁ·µå ×æÜÝ¾øé²ìåê ‡¼åÉÄåÆÁµå

ÕÜÈå¾üï¼å²µåëÇÈå

(a) Soluble Ocular Drug

Indicator.

(b) Soluble Oral Drug Insert.

(c) Soluble Ocular Drug Insert.

(d) Safe Ocular Drug Insert.

35. † ’ðâÿå˜™Äå ²ìåìæÔåíúÁµåê ÜÈåÔð¼å’ðë”âÿå˜µæ˜µåÁµå

§âÿåÜÈðé²™’ð²ìåìæ˜™Áµð ?

(a) ’å²µå µåÊÑÓ ƒ’åêÏÑæ²µó µåÐ µó …ÄåÞ¯ó¤

(b) ÑæÏ“ÐÜÈå¯ó¤

(c) „’åêÏÜÈå¯ó¤

(d) ÕêÅ´™ÜÈó”

36. ôåÔåê¤Áµå ÇÈæ²µå˜µåÔåêÏ¼ð²ìåê ÇÈåÐÔåìæ¸Áµå²µå

ÔåÄåêÆ ’ðâÿå’åÒ´µåÒ¼ð ½â–ÜÈåÑæ˜µåê¼å¾Áµð.

(a) dQ

dt = Cd – Cr

(b) dQ

dt = Ps (Cd – Cr)

(c) dQ

dt = – Ps (Cd – Cr)

(d) – dQ

dt = – Ps (Cr – Cd)

27 (13 – A)

31. Permeability of oral mucosa

decreases in the order

(a) Sublingual, Buccal and Palatal.

(b) Buccal, Sublingual and Palatal.

(c) Palatal, Buccal and Sublingual.

(d) Buccal, Palatal and Sublingual.

32. Sterile rod shaped devices made

up of hydroxypropyl cellulose

used in the treatment of dry eye

syndrome is

(a) SODI

(b) Minidisc

(c) OTS

(d) Lacrisert

33. Surface morphology of

Pharmaceutical formulation can

be investigated by using

(a) UV spectroscopy

(b) Scanning Electron

Microscopy

(c) FTIR spectrophotometer

(d) Differential scanning

colourimetry.

34. Pharmaceutical product SODI

stands for

(a) Soluble Ocular Drug Indicator.

(b) Soluble Oral Drug Insert.

(c) Soluble Ocular Drug Insert.

(d) Safe Ocular Drug Insert.

35. Which of the following is non-

erodible insert ?

(a) Soluble Ocular Drug Insert

(b) Lacrisert

(c) Ocusert

(d) Minidisc

36. The rate of skin permeation is

given by

(a) dQ

dt = Cd – Cr

(b) dQ

dt = Ps (Cd – Cr)

(c) dQ

dt = – Ps (Cd – Cr)

(d) – dQ

dt = – Ps (Cr – Cd)

27 (14 – A)

37. † ’ðâÿå˜™ÄåÔåíú˜µåâÿåÑ–Ó ÜÝÒÁ¿·µð°’ó

ŠÑæÜÈðë±éÔåê²µó ²ìåìæÔåíúÁµåê ?

(a) ÜÈðÑêÏÑðëéÜÈó ™²µðñÔðé°Ôó

(b) ÇÈæÑ– ÊêÏ¯æ´™²ìðêÄó

(c) ¦ÿðÑæ°Äó

(d) ŠÇÈæ“Þ

38. † ’ðâÿå˜™ÄåÔåíú˜µåâÿåÑ–Ó ƒ²ìåìæÅÄå ÜÈåÇ·Èð¤’ð±Ò¯ó

²ìåìæÔåíúÁµåê ?

(a) ÇÈåíÓ²µðëéÅ’ó F127

(b) ÜÈðëé´™²ìåêÒ ´™ƒ“Þ’ðëÑðé¯ó

(c) ÜÈðëé´™²ìåêÒ ¯æ²µó ™Ó’ðë’ðëÑðé¯ó

(d) ´™’ðëé ™ÜÝÑó ÕêÁ¿·µðñÑó ÜÈåÑæÉÃ’ðÞûñ µó

39. Á¿·µåÒÊó ¯æÏ’ó ÇÈå²™é’ðÛ²ìåêÄåêÆ † ’ðâÿå ™Äå

ÔåìòÑÏÔåìæÇÈåÄå’æ”˜™ ÊâÿåÜÈåê¼æ¾²µð ?

(a) ¯æÐÄóÞ´µåÔåê¤Ñó ÇÈæÏôó˜µåâÿåê

(b) õ²µåÑó ’æÒ¯æÐÜÈðÇÝ±Ôó µåâÿåê

(c) Ôåìæ¼ðÐ˜µåâÿåê

(d) Ôåêë˜™Äå ÜÝÒÇÈå²µå’å˜µåâÿåê

40. ’ðâÿå’åÒ µå ÇÈåÁµåÂÃ½²ìåêÑ–Ó ›åÄå²µåëÇÈåÁµå ËÚÈåÁ·™˜µåâÿåÄåêÆ ßðñ µðëÐéÇ·ÝÑ–’ó ƒÁ¿·µåÔæ ÑðñÇÈðîÇ·ÝÑ–’ó ÇÈæÑ–Ôåê²µó ÔåìæÏ°Ð’óÞÄåÑ–Ó Õ¼å²™ÜÈåÑæ˜µåê¼å¾Áµð

(a) ƒ´µðáÜÝÔó ™Ç·ÈåùíþÏ×åÄó Å²ìåêÒ½Ð¼å ÇÈåÁµåÂÃ½

(b) ÔðêÒÊðÐéÄó Ôåìæ´µåêÏÑðé ð µó ÇÈåÁµåÂÃ½

(c) ÔåìæÏ°Ð’óÞ ´™ÜÈóÇÈå×å¤Äó ÔåìæÁµå²™ ÇÈåÁµåÂÃ½

(d) Ôðêñ’ðëÐé ²™ÜÈåÔæ¤²ìåê²µó ÇÈåÁµåÂÃ½

41. §ÒÁµåê ’åÒÇÈæ®¤ÔðêÒ¯ó Ôåìæ´µðÑó † ’ðâÿå’åÒ µå ÇÈåÐ½“Ð²ìðê²ìåêÄåêÆ ƒÄåêÜÈå²™ÜÈåê¼å¾Áµð.

(a) ÔðëÁµåÑ Ôå˜µå¤Áµå ÇÈåÐ½“Ð²ìðê

(b) Š²µå µåÄðé Ôå˜µå¤Áµå ÇÈåÐ½“Ð²ìðê

(c) ×åëÄåÏ Ôå µå¤Áµå ÇÈåÐ½“Ð²ìðê

(d) ÔðêéÑ–Äå Ôåêë²µåê ÇÈåÐ½“Ð²ìðê˜µåâÿåê

42. Coacervation ÇÈåÐ¼ðÏé“é’å²µå ¼åÒ¼åÐÁµå ÔåêëÑ’å Ôðêñ’ðëÐé ’æÏÇÈåîÞÑó˜µåâ– µð ÑðéÇÈåÄå Ôåìæ´µåêÔåíúÁµå’æ”˜™ ’ðâÿå’åÒ µå ÇÈåÁµæÁ¿·µå¤ÔåÄåêÆ ÊâÿåÜÈåÑæ˜µåê¼å¾Áµð.

(a) Åé²™ÄåÑ–Ó ’å²µå˜µåêÔå ÇÈæÑ–Ôåê²µó

(b) Åé²™ÄåÑ–Ó ’å²µå˜µåÁ™²µåêÔå ÇÈæÑ–Ôåê²µó

(c) Õ²µåêÁµåÂÃ ôæ¦ÿó¤ „˜™²µåêÔå „²µðëé-ÜÈæÑó˜µåâÿåê

(d) ’å ™Ôðê ÔåìæÑ–’åêÏÑæ²µó ¼åë’åÁµå Ñ–ÇÝ´µó˜µåâÿåê

27 (15 – A)

37. Which of the following is

Synthetic elastomer ?

(a) Cellulose derivative

(b) Poly butadiene

(c) Gelatin

(d) Epoxy

38. Which of the following is an

ionic surfactant ?

(a) Pluronic F127

(b) Sodium deoxycholate

(c) Sodium taurglycocholate

(d) Decodecyl methyl sulphoxide

39. Thumb tack test is used to

evaluate

(a) Transdernal patches

(b) Oral contraceptives

(c) Tablets

(d) Nasal sprays

40. Following is the system in which

solid drugs are dispersed in a

hydrophilic or lipophilic polymer

matrix :

(a) Adhesive diffusion controlled

system

(b) Membrane modulated system

(c) Matrix dispersion type

system

(d) Micro reservoir system

41. One compartment model follows

(a) 1st order reaction

(b) 2nd

order reaction

(c) zero order reaction

(d) All above three

42. Following is the material used for

coating microcapsules by

Coacervators separation

technique :

(a) Water soluble polymer.

(b) Water insoluble polymer.

(c) Oppositely charged aerosols.

(d) Low molecular weight lipids.

27 (16 – A)

43. ËÚÈåÁ·µå ×æÜÝ¾øé²ìåê ÅÕê¤½˜µåâÿåÑ–Ó QbD

ŠÒÊêÁµå²µå ÕÜÈå¾üï¼å²µåëÇÈå

(a) ’æÖÑ–° Êðñ ´™ÜÈðñÄó

(b) ’æÖÒ°° Êðñ ´™ÜÈðñÄó

(c) ’æÖÒ°° Êðñ ´™Ç·ÈåùîÏ×åÄó

(d) ’æÖÑ–° Êðñ ´™Ç·ÈåùîÏ×åÄó

44. † ’ðâÿå˜™Äå ²ìåìæÔåíúÁµåê ÄæÄó ´™ µðÐé µåÊÑó

ÜÝÒÁ¿·µð°’ó ÇÈæÑ–Ôåê²µó˜µåâ–˜µð ‡Áµæßå²µå¹ð ?

(a) ÇÈæÑ– ŠÁ¿·™Ñ–éÄó ˜µðÓüñ’æÑó

(b) ´µð’óÞ¯æÐÄó

(c) ’ðñ ðëéÜÈæÄó

(d) „Ñó¨Äðé¯ó

45. † ’ðâÿå ™Äå ²ìåìæÔåíúÁµåê ™ µðÐé µåÊÑó ÇÈæÑ–

Ôåê²µó µð ‡Áµæßå²µå¹ð²ìåìæ˜™Áµð ?

(a) HPMA ’ðëéÇÈæÑ–Ôåê²µó

(b) ’æÊæ¤“Þ ÕêÁ¿·µðñÑó ’ðñ°Äó

(c) ÇÈæÑ–ŠÁ¿·™Ñ–Äó ˜µðÓüñ’æÑó

(d) DIVEMA

46. Ç·ÈðùîúÓé°Ò˜µó ´µåÐ˜µó µðÑ–Ôå²™ ÜÝÜÈå±Ôåìó Äå

²µæØÜÈæÒÁµåÐ¼ð²ìåêê ˜µæÏÜÝ±ø’ó ÁµåÐÔå µåâ–˜™Ò¼å

_____ „˜™²µåê¼å¾Áµð.

(a) ’å ™Ôðê

(b) ßðôåê¢

(c) ƒÁµå²µåÚÈð±é

(d) ƒÁµå²µåÚÈð±é ƒÁ¿·µåÔæ ßðôåê¢

47. † ’ðâÿå˜™ÄåÁµåê ßðñ µæÐ“ÞÇÈðîÐÇÈðñÑó ÕêÁ¿·µðñÑó

ÜÈðÑêÏÑðëéÜÈó Äå ÜÈåÔåìæÄæÁ¿·µå¤’å ÇÈåÁµåÔåÑÓ

(a) ÜÈðÑêÏÑðëéÜÈó

(b) Êðé“Ò˜µó ÜÈðëé´µæ

(c) ÕêÁ¿·µðëéÜÝÑó

(d) Ç·ÈæÔåìæ¤’ðëé¯ó

48. §ÒÁµåê ËÚÈåÁ·µå ×æÜÝ¾øé²ìåê ÅÕê¤½²ìåê

ÜÝÀ²µå¼ð²ìåêÄåêÆ ’åê²™¼å ƒÁ·µåùÏ²ìåêÄå˜µåâÿåÄåêÆ Äå µðÜÝ

ƒÁµå²µå _____ÄåêÆ ÅÁ·µå¤²™ÜÈåÑæ˜µåêÔåíúÁµåê.

(a) ƒÁ·µå¤ „²ìåêêÚÈåÏ

(b) ’åÇÈæ®ê Êæâ–’ð

(c) ÜÈå²µæÜÈå²™ (Mean) ƒ²ìåêêÚÈåÏ

(d) ’å²¿™¸¼ð

27 (17 – A)

43. In pharmaceutical formulation

QbD Stands for

(a) Quality by design

(b) Quantity by design

(c) Quantity by diffusion

(d) Quality by diffusion

44. Which of the following is the

example for non-degradable

synthetic polymer ?

(a) Polyethylene Glycol

(b) Dextran

(c) Chitosan

(d) Alginate

45. Which of the following is the

example for degradable polymer ?

(a) HPMA Copolymer

(b) Carboxy methyl chitin

(c) Polyethylene Glycol

(d) DIVEMA

46. Floating drug delivery system

have a bulk density ______ than

Gastric fluids.

(a) less

(b) more

(c) same as

(d) either same or more

47. Following is not the synonym for

Hydroxy propyl methyl

cellulose :

(a) Cellulose

(b) Backing Soda

(c) Methocel

(d) Pharmacoat

48. Stability studies of a

pharmaceutical formulation is

carried out to determine its

(a) half life

(b) shelf life

(c) mean life

(d) hardness

27 (18 – A)

49. ÄåÕéÄå µåÐ µó ´µðÑ–Ôå²™ ÇÈåÁµåÂÃ½²ìåêÑ–Ó, ßðñ µæÐ“ÞÇÈæÐÇÝ ÕêéÁ¿·µðñÑó ÜÈðÑêÏÑðëéÜÈó ÄåêÆ _____ „˜™ ÊâÿåÜÈåê¼æ¾²µð.

(a) ÜÈåÒ²µå’åÛ’å ÔåÜÈåê¾

(b) ²µðé¯ó ’åÒ ðëÐéÑ–Ò µó ÇÈæÑ–Ôåê²µó

(c) ÜÝà’æ²µå’å ÔåÜÈåê¾

(d) “Ð²ìåìæØéÑ ËÚÈåÁ·µå ×æÜÝ¾øé²ìåê ›å®’å

50. ICH ŠÒÊêÁµå²µå ÕÜÈå¾üï¼å²µåëÇÈå

(a) …Ò®²µóÄæÏ×åÄåÑó ’æÄóÇ·Èð²µðÄóÞ „Ç·Èó ßæÜÝÉ®ÑóÞ

(b) …Ò®²µóÄæÏ×åÄåÑó ’æÄóÇ·Èð²µðÄóÞ „Ç·Èó ßæÔðë¤éÄðñÜÈðé×åÄó

(c) …Ò´™²ìåìæÜÈó ÜÈå°¤Ç·Èðñ µó ßæÜÝÉ®ÑóÞ

(d) …Ò´™²ìåêÄó ’æÄóÇ·Èð²µðÄóÞ „Ç·Èó ßæÜÝÉ®ÑóÞ

51. ’åÒÇÈæ®¤ÔðêÒ¯ó Ôåìæ´µðÑ–Ò˜µó, ËÚÈåÁ·µåÔðîÒÁµå²µå ´™ÜÈðëÉÜÝ×åÄó ’åê²™¼å Ç·ÈæÔåê¤’ðë’ðñÄð°’óÞ ÄåêÆ ÕÔå²™ÜÈåê¼å¾Áµð.

(a) ÊâÿåÜÈåÊðé’æÁµå ÜÈåÔåê²ìåê ßæ˜µåë ÇÈåÐÊÑ¼ð²ìåê ƒÒ×å˜µåâÿåê

(b) ²µå’å¾Áµå ßå²™ÕÄå Êâÿå’ð Ôåê¼åê¾ ÇÈæ°¤×åÄó ˜µåê¹æÒ’å

(c) ÁµðéßåÁµå ƒÒ˜µæÒ×å µåâÿå Äå´µåêÔå¸ ²µðé¯ó Å²ìåê¼æÒ’åÁµå ÁµåïÚÝ±

(d) ÊâÿåÜÈåÊðé’æÁµå ÇÈåÐÊÑ¼ð Ôåê¼åê¾ ÇÈæ°¤×åÄó ˜µåê¹æÒ’å

52. “§Äó ’åÒÇÈæ®¤ÔðêÒ¯ó õÇÈåÄó Ôåìæ´µðÑó” ÄåÑ–Ó õÇÈåÄó ŠÒÊ ÇÈåÁµå ‹ÄåÄåêÆ ÜÈåë¡ÜÈåê¼å¾Áµð ?

(a) àé²™’ð Ôåê¼åê¾ Ôå¦¤Äð˜µåâÿåê §ÒÁµðé Á™“”ÄåÔåíú

(b) àé²™’ð Ôåê¼åê¾ Ôå¦¤Äð˜µåâÿåê §ÒÁµðé Á™“”ÄåÔåíú Ôåê¼åê¾ ÔåÏÔåÜÈðÀ²ìåêê „²µåÒÊ·åÁµåÑ–Ó Åé´™Áµå ´µðëéÜÈåÄåêÆ ’åâÿðÁµåê’ðëÒ ™Áµð

(c) àé²™’ð Ôåê¼åê¾ Ôå¦¤Äð˜µåâÿåê §ÒÁµðé Á™“”ÄåÔåíú Ôåê¼åê¾ ÔåÏÔåÜÈðÀ²ìåêê „²µåÒÊ·åÁµåÑ–Ó Åé´™Áµå µðëéÜÈó ƒÄåêÆ ‡â–ÜÝ’ðëÒ´™Áµð

(d) àé²™’ð Ôåê¼åê¾ Ôå¦¤Äð˜µåâÿåê §ÒÁµðé Á™“”ÄåÔåÑÓ Ôåê¼åê¾ ÔåÏÔåÜÈðÀ²ìåêê „²µåÒÊ·åÁµåÑ–Ó Åé´™Áµå µðëéÜÈó ƒÄåêÆ ’åâÿðÁµåê’ðëÒ ™Áµð.

53. ’åÒÇÈæ¯ó¤ÔðêÒ¯ó Ôåìæ´µðÑ–Ò˜µó µð ÜÈåÒÊÒÁ·™ÜÝÁµåÒ¼ð † ’ðâÿå ™Äå ²ìåìæÔå Ñ’åÛ¸Ôåíú ÜÈå²™²ìåìæ˜™Áµð ?

(a) …Áµåê §ÒÁµåê ÔæÜÈå¾ÔåÔæÁ™é ÁµåïÚÝ±’ðëéÄå ‹’ðÒÁµå²µð …Áµåê ×å²™é²µåÕ¦ÿæöÄå ßæ˜µåë ƒÒ˜µå²µåôåÄæ Ôåìæà½²ìåêÄåêÆ „Áµå²™ÜÝÁµð.

(b) ˜µåº½é²ìåê ôåÑÄð²ìåêê Äðé²µåÔåêê• ÁµæÂ˜™Áµð.

(c) ƒÒ˜µæÒ×å ËÚÈåÁ·µåÁµå ÇÈåÐÊÑ¼ð ßæ˜µåë ÊðñÒ ™Ò˜µó µåâÿåê ˜µðë½¾²µåêÔð´µð²ìåêÑ–Ó …Áµåê Êâÿå’ð²ìåìæ˜µåê¼å¾Áµð.

(d) ËÚÈåÁ·µåÁµå ADME ²ìåê ’æ²ìåê¤ÕÁ·µæÄåÔåÄåêÆ ÕÔå²™ÜÈåÑê ÜÈæÁ·µåùÏÕÑÓ.

27 (19 – A)

49. In Novel Drug Delivery system,

Hydroxy propyl methyl cellulose

is used as

(a) Preservative

(b) Rate controlling polymer

(c) Sweetening agent

(d) Active pharmaceutical

ingredient

50. ICH stands for

(a) International Conference of

Hospitals.

(b) International Conference on

Harmonisation.

(c) India’s Certified Hospitals.

(d) Indian Conference of

Hospitals.

51. Compartment modeling describes

the pharmacokinetics of drug

disposition

(a) Using time and

concentration parameters.

(b) Using blood flow and

partition coefficient.

(c) Between body tissues in

terms of rate constant.

(d) Using concentration and

partition coefficient.

52. In “One compartment open

model” the term open indicates :

(a) Absorption and elimination

are unidirectional.

(b) Absorption and elimination

are unidirectional and the

system has lost the dose

initially introduced.

(c) Absorption and elimination

are unidirectional and the

system retains the dose


(d) Absorption and elimination

are not unidirectional and

the system has lost the dose


53. Which of the following feature of

compartment modeling is true ?

(a) It is realistic approach since

it is based on physiological

and anatomy information.

(b) Mathematical movement is

straight forward.

(c) Used where tissue drug

concentration and binding

are known.

(d) Mechanism of drug’s ADME

cannot be explained.

27 (20 – A)

54. Ôåêë¼åÐ¦Äå’æÒ˜µå ÕÜÈå¦¤Äð²ìåê Áµå¼æ¾Ò×å

Á™ÒÁµå KE ²ìåêÄåêÆ Å¸¤ÎêÜÈåÑê †

’ðâÿå ™Äå ÕÁ·µæÄåÔåÄåêÆ ÊâÿåÜÈåÑæ˜µåê¼å¾Áµð

(a) ÕÜÈå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå ÕÁ·µæÄå

Ôåê¼åê¾ ÜÝ˜µæÍ ÔðêñÄåÜÈó ÕÁ·µæÄå

(b) ²µðÜÝ µåêÏ²ìåêÑó˜µåâÿå ÕÁ·µæÄå Ôåê¼åê¾

ÜÝ˜µæÍÔðêñÄåÜÈó ÕÁ·µæÄå

(c) ÕÜÈå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå²µå Ôåê¼åê¾

²µðÜÝ µåêÏ²ìåêÑó˜µåâÿå ÕÁ·µæÄå

(d) ÔæÏ˜µåÆ²µó-ÄðÑÞÄó ÕÁ·µæÄå Ôåê¼åê¾

²µðÜÝ µåêÏ²ìåêÑó˜µåâÿå ÕÁ·µæÄå

55. ÊæßåÏ ²µå’å¾Äæâ–é²ìåê Åé´™’ð˜µð “àé²™’ð²ìåê

ÇÈåÐÔåìæ¸Áµå²µåÔåíú Ôå¦¤Äð²ìåê ÇÈåÐÔåìæ¸“”Ò¼å

˜µåÔåêÄæßå¤Ôæ ™ ßðôæ¢˜™²µåê¼å¾Áµð.”

ÜÈåÒÇÈåî¸¤àé²™’ð²ìðëÒÁ™˜µð …Áµåê ’ðâÿå’åÒ µå

ƒÒ×åÔåÄåêÆ ÜÈåë¡ÜÈåê¼å¾Áµð.

(a) ÇÈæÓÜÈæÍ ÜÈæÒÁµåÐ¼ð²ìåê ÔåÏ¼æÏÜÈåÔåíú

Ôå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå²µåÔåÄåêÆ ƒÔåÑÒÊ–-

ÜÝ²µåêÔåíúÁ™ÑÓ. (Ôåêê’å¾Ôæ ™²µåê¼å¾Áµð)

(b) ÇÈæÓÜÈæÍ ÜÈæÒÁµåÐ¼ð²ìåê ÔåÏ¼æÏÜÈåÔåíú

Ôå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå²µåÔåÄåêÆ

Ôåìæ¼åÐÔðé ƒÔåÑÒÊ–ÜÝ²µåê¼å¾Áµð.

(c) ÇÈæÓÜÈæÍ ÜÈæÒÁµåÐ¼ð²ìåêê

ÊÁµåÑæ˜µåêÔåíúÁ™ÑÓ.

(d) Ôå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå²µåÔåíú

ÜÝÀ²µåÔæ˜™²µåê¼å¾Áµð.

56. ’ðâÿå ™ÄåÔåíú µåâÿåÑ–Ó ²ìåìæÔå ßðéâ–’ð ÜÈå²™²ìåìæ ™Áµð ?

(a) Á™é›å¤ÔæÁµå ƒÁ·µå¤ ƒ²ìåêêÚÈåÏ

ßðëÒÁ™²µåêÔå ËÚÈåÁ·™ µåâ– µð,

ÕÜÈåå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå ÕÁ·µæÄåÁµåÑ–Ó

Ôåêë¼åÐÔåÄåêÆ 7 ²™ÒÁµå 8 ƒÁ·µå¤

ƒ²ìåêêÚÈåÏ µåâÿåÔå²µð˜µð ÜÈåÒ˜µåÐàÜÈåÊðé’åê.

(b) ÕÜÈå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå²µåÁµå ÕÁ·µæÄå

ÁµåÑ–Ó, ËÚÈåÁ·µå Ôå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå

‹²™â–¼å˜µåâÿåÄåêÆ µåÔåêÅÜÈåÑæ˜µåêÔåíúÁ™ÑÓ.

(c) Š²µå µåê ÕÁ·µæÄå µåâÿå Ôåêë¼åÐÁµå¼æ¾Ò×å-

Á™ÒÁµå ÔðëÁµåÑ Ôå˜µå¤Áµå Ôå¦¤Äð²ìåê

ÇÈåÐÔåìæ¸Áµå²µå Å²ìåê¼æÒ’å˜µåâÿåÄåêÆ

˜µå¸Äð Ôåìæ µåÑæ˜µåêÔåíúÁ™ÑÓ.

(d) Á™é›å¤ÔæÁµå ƒÁ·µå¤ ƒ²ìåêêÚÈåÏ

ßðëÒÁ™²µåêÔå ËÚÈåÁ·™˜µåâ–˜µð ÜÝ˜µæÍ

ÔðêñÄåÜÈó ÕÁ·µæÄåÁµåÑ–Ó Ôåêë¼åÐÔåÄåêÆ 7

²™ÒÁµå 8 ƒÁ·µå¤ ƒ²ìåêêÚÈåÏ˜µåâÿåÔå²µð˜µð

ÜÈåÒ˜µåÐàÜÈåÊðé’åê.

57. 300 mg ²ìåê IV ÊðëéÑÜÈó Äå ÄåÒ¼å²µå,

ƒÒÁµæ¨ÜÈåÑæÁµå „²µåÒÊ–·’å ÇÈæÓÜÈæÍ

ÜÈæÒÁµåÐ¼ð²ìåêê 20 mg/L. „˜™Áµð. Õ¼å²µå¹ð µð

ÜÈåÒÊÒÁ·™ÜÝÁµå ¼ðëé²™’ð²ìåê ˜µæ¼åÐ ŠÚÈåê± ?

(a) 15 L

(b) 10 L

(c) 20 L

(d) 5 L

27 (21 – A)

54. Which of the following methods

is used to determine KE from

urinary excretion data ?

(a) Rate of excretion method

and sigma minus method.

(b) Method of residuals and

sigma minus method.

(c) Rate of excretion and

Method of residuals.

(d) Wagner-Nelson method and

method of residuals.

55. For extra vascular administration,

‘Absorption rate is significantly

greater than Elimination rate’

with the complete absorption

indicating

(a) Change in plasma

concentration is independent

of elimination rate.

(b) Change in plasma

concentration is dependent

only on elimination rate.

(c) Plasma concentration does

not change.

(d) Elimination rate remains

constant.

56. Which one of the following

statement is correct ?

(a) For drugs having long half-

lives, urine has to be

collected for 7 to 8 half-

lives in excretion rate

method.

(b) Fluctuations in the rate of

drug elimination are not

observed in rate of excretion

method.

(c) First order elimination rate

constants cannot be

computed from urine data

by two methods.

(d) For drugs having long half-

lives, urine has to be

collected for 7 to 8 half- lives

in sigma minus method.

57. The initial plasma concentration

estimated after an IV bolus of

300 mg is 20 mg/L. What is the

apparent volume of distribution ?

(a) 15 L

(b) 10 L

(c) 20 L

(d) 5 L

27 (22 – A)

58. ’ðâÿå ™ÄåÔåíú˜µåâÿåÄåêÆ ÇÈå²™ØéÑ–ÜÝ.

1. ËÚÈåÁ·™²ìåê Á¿·µð²µåÇÝ±’óÞ …Ò´µð’óÞ

2. ËÚÈåÁ·™²ìåê ƒÁ·µå¤„²ìåêêÚÈåÏ

3. ´µðëéÜÝÒ˜µóÄå ƒÄåê’åëÑ¼ð ËÚÈåÁ·™²ìåê ÜÈæÒÁµåÐ¼ð²ìåêÄåêÆ Á¿·µð²µæÇÝ±’ó

ÕÒ µðëéÁµå ÇÈå²™Õê½²ìåêÑ–Ó ’æ²ìåêêÂ’ðëâÿåäÑê ÔðêéÑ–Äå ²ìåìæÔå ƒÒ×å µåâÿåê ’æ²µå Ôæ µåê¼å¾Ôð ?

(a) 1, 2

(b) 1, 3

(c) 2, 3

(d) 1, 2, 3

59. ÔåêÄåêÚÈåÏ²µåÑ–Ó ËÚÈåÁ·™²ìåê Ôðê®ÊæÑ–ÜÈåÒÄå ÔðêéÑð ²ìåê’åï½¾Äå ’æÎêÑð˜µåâÿå ÇÈå²™¹æÔåê˜µåâÿåÄåêÆ ÇÈå²™ØéÑ–ÜÈåêÔåíúÁµå’ð” ÊâÿåÜÈåêÔå ÔåìæÁµå²™ ËÚÈåÁ·™ ²ìåìæÔåíúÁµåê ?

(a) “Ð²ìåìæ°ÄðñÄó

(b) ´µðñ’åêÔåê²µæÑó

(c) „Ò°ÇÈðñ²™éÄó

(d) Ç·ÈðÅ¯æÎêÄó

60. ÊßåêÊæ²™²ìåê µðëéÜÝÒ˜µó Äå ƒÔåÁ·™²ìåêÑ–Ó ŠÚÈåê± ÇÈåÐÔåìæ¸Áµå ËÚÈåÁ·™²ìåêê ÁµðéßåÁµåÑ–Ó ÜÈåÒôå²ìåêÔæ˜™²µåê¼å¾Áµð ŠÒÊêÁµåê ’ðâÿå’åÒ µå ƒÒ×åÔåÄåêÆ „Á·µå²™ÜÝ²µåê¼å¾Áµð.

1. ´µðëéÜÈó Äå ˜µæ¼åÐ

2. ´µðëéÜÝÒ˜µó Äå µåêÕÄå ƒÒ¼å²µå

3. Ôå¦¤Äð²ìåê ƒÁ·µå¤ ƒ²ìåêêÚÈåÏ ’ðâÿå ™Äå ÜÈåÒ’ðé¼å µåâÿåÄåêÆ ÊâÿåÜÝ ÜÈå²™²ìåìæÁµå

‡¼å¾²µå „²™ÜÝ.

(a) 1 Ôåê¼åê¾ 2

(b) 2 Ôåê¼åê¾ 3

(c) 1 Ôåê¼åê¾ 3

(d) 1, 2 Ôåê¼åê¾ 3

61. ÊßåêÜÈåÑÁµå µðëéÜÝÒ˜µó ÄåÑ–Ó, ÜÝÀ²µåÜÝÀ½²ìåêÄåêÆ

¼åÑêÇÈåíúÔåíúÁµå’ð” Êðé’æ˜µåêÔå ’æÑÔåíú ’ðâÿå’åÒ´µå

ƒÒ×å˜µåâ–ÒÁµå Å¸¤²ìåêÔæ˜µåê¼å¾Áµð.

(a) ´µðëéÜÈó Äå ˜µæ¼åÐ

(b) ´µðëéÜÝÒ˜µó Äå µåêÕÄå ƒÒ¼å²µå

(c) ´µðëéÜÈó µåâÿå ÜÈåÒ•ÿðÏ

(d) §®ê± Ôå¦¤Äð²ìåê ÇÈåÐÔåìæ¸Áµå

Å²ìåê¼æÒ’å (KE)

62. ßðÇÈæÏ°’ó ‹²µåêÇÈðé²™ÅÒÁµå, ’ðâÿå’åÒ µå

ËÚÈåÁ·™²ìåê Ôå¦¤Äð²ìåêê ÊÁµåÑæ˜µåêÔåíúÁ™ÑÓ.

(a) ÔåìæÇ·Ý¤Äó

(b) Ôæ²µóÇ·Èæ²™Äó

(c) Á¿·™²ìðëéÇ·ÝÑðñÄó

(d) Äðñ ðëÐé ™ÓÜÈå²™éÄó

63. àé²™’ð²ìåê ›å®±Áµå ÄåÒ¼å²µåÁµå ƒÔåÁ·™²ìåêÑ–Ó

(a) àé²™’ð²ìåê Áµå²µåÔåíú Ôå¦¤Äð²ìåê

Áµå²µå“”Ò¼å ßðôæ¢˜™²µåê¼å¾Áµð.

(b) Ôå¦¤Äð²ìåê Áµå²µåÔåíú àé²™’ð²ìåê

Áµå²µå“”Ò¼å ßðôæ¢˜™²µåê¼å¾Áµð.

(c) àé²™’ð²ìåê Áµå²µåÔåíú ÜÈðëÄðÆ²ìåìæ˜µåê¼å¾Áµð

(d) ²ìåìæÔåíúÁµðé Ôå¦¤Äð²ìåêê Äå µð²ìåêêÔåíúÁ™ÑÓ

27 (23 – A)

58. Consider the following :

1. The therapeutic index of the

drug.

2. The half-life of the drug.

3. Convenience of dosing

Which of the above factors are

responsible for maintaining drug

concentration within the

therapeutic window ?

(a) 1, 2

(b) 1, 3

(c) 2, 3

(d) 1, 2, 3

59. The model drug to investigate the

effects of liver diseases on drug

metabolism in man is

(a) Creatinine

(b) Dicumarol

(c) Antipyrine

(d) Phenytoin

60. The extent of drug accumulation

in the body during multiple

dosing is dependent of

1. Dose size

2. Dosing interval

3. Elimination half-life

Choose the answer using the

codes :

(a) 1 & 2

(b) 2 & 3

(c) 1 & 3

(d) 1, 2 & 3

61. The time taken to reach steady-

state in multiple dosing is

determined by

(a) Dose size

(b) Dosing interval

(c) Number of doses

(d) Total elimination rate

constant (KE)

62. The elimination of one of the

following drug is not changed by

the hepatic impairment :

(a) Morphine

(b) Warfarin

(c) Theophylline

(d) Nitroglycerine

63. During post absorption phase

(a) Absorption rate is greater

than elimination rate.

(b) Rate of elimination is

greater than absorption rate.

(c) Absorption rate becomes

zero.

(d) No elimination takes place.

27 (24 – A)

64. ˜µå²™ÚÈå³ ÇÈæÓÜÈæÍ ÜÈæÒÁ™Ðé’å²µå Ôåíú ’ðâÿå’åÒ µå

ƒÒ×åÔåÄåêÆ ƒÔåÑÒÊ–ÜÝ²µåê¼å¾Áµð.

(a) Åé´™’ð²ìåê Áµå²µå Ôåê¼åê¾ Ôå¦¤Äð²ìåê

Áµå²µå

(b) Åé´µåÑæÁµå ´µðëéÜÈó, àé²™’ð²ìåê Áµå²µå

Ôåê¼åê¾ Ôå¦¤Äð²ìåê Áµå²µå

(c) Åé´™’ð²ìåê ÜÈåÔåê²ìåê, àé²™’ð²ìåê Áµå²µå


(d) Åé´™’ð²ìåê Ôåìæ˜µå¤, àé²™’ð²ìåê Áµå²µå


65. 40 mg ´µðëéÜÈó ÄåÑ–Ó ËÚÈåÁ·™²ìåêÄåêÆ

Åé´™Áµæ˜µå, „²µåÒÊ·åÁµå ÜÈæÒÁµåÐ¼ð²ìåêê 0.5

µg/ml. „˜™²µåêÔåíúÁµåê ’åÒ´µåê ÊÒÁ™¼åê.

ËÚÈåÁ·™²ìåê ƒÁ·µå¤ƒ²ìåêêÚÈåÏ 2 ˜µåÒ ð ŠÒÁµåê

’ðë°±ÁµåÂ²µð, † ËÚÈåÁ·™²ìåêê ÜÈåÒÇÈåî¸¤ ½â–

˜µðëâÿåêäÔå Ñð’å” ŠÚÈåê± ?

(a) 27.68 l/˜µåÒ ð µð

(b) 29.48 l/˜µåÒ ð µð

(c) 25.48 l/˜µåÒ ð µð

(d) 29.87 l/˜µåÒ ð µð

66. † ’ðâÿå ™ÄåÔåíú˜µåâÿåÑ–Ó ²ìåìæÔå ÕÔå²µå¹ð ¼åÇÈæÉ ™Áµð ?

(a) ÜÈæÆ²ìåêê ƒÒ µæÒ×å’ð” ßðëéÑ–ÜÝÁµæ µå ƒ´™ÇÈðîéÜÈó ƒÒ˜µæÒ×åÁµåÑ–Ó Åé²™Äå ÇÈåÐÔåìæ¸ ’å ™Ôðê …²µåê¼å¾Áµð.

(b) Ôå²ìåêÜÈå”²™ ™Ò¼å ÄåÔå¦ÿæ¼å Ø×åê˜µåâÿåÑ–Ó Õ¼å²µå¹æ µæ¼åÐ˜µåâÿåê ßðôæ¢ ™²µåêÔåÒ¼ð ¼ðëé²µåê¼å¾Áµð.

(c) Ñ–ÇÝ´µó ÄåÑ–Ó ’å ™Ôðê ’å²µå µåêÔåÒÁ¿·µå ËÚÈåÁ·™˜µåâÿåê Ôå²ìåêÜÈå”²µåÑ–Ó ƒÁ·™’å ÇÈåÐÔåìæ¸ÁµåÑ–Ó Õ¼å²µå¹ð²ìåìæ˜µåêÔåÒ¼ð ¼ðëé²µåê¼å¾Áµð.

(d) ËÚÈåÁ·™²ìåê ƒÁ·µå¤ ƒ²ìåêêÚÈåÏÔåÄåêÆ „Á·µå²™ÜÝ ´µðëéÜÝÒ µó Äå´µåêÕÄå ƒÒ¼å²µå µåâÿåÄåêÆ Ñð’å”ßæ’åÑæ˜µåê¼å¾Áµð.

67. ’ðâÿå ™ÄåÔåíú˜µåâÿåÄåêÆ ÜÈå²™ ßðëÒÁ™ÜÝ.

ÇÈå°± – I ÇÈå°± – II

A. ÜÝÀ²µåÜÝÀ½²ìåêÑ–Ó ÜÈå²µæÜÈå²™ ËÚÈåÁ·™ ÜÈæÒÁµåÐ¼ð

1. 1

(1– eKEτ

)

B. ÜÈåÒôå²ìåêÄåÁµå ÜÈåë¡

2.1

(1– eKaτ) (1– eKEτ)

C. Ñðëé´™Ò µó ´µðëéÜÈó 3.

1

(1– eKEτ

)

D. i.v.²ìåêÑ–Ó Ñðëé´™Ò µó ´µðëéÜÈó

4. FX0

ClTτ

Codes :

A B C D

(a) 3 4 1 2

(b) 4 3 1 2

(c) 4 3 2 1

(d) 3 1 4 2

27 (25 – A)

64. The peak plasma concentration

depends upon

(a) Rate of administration and

rate of elimination.

(b) Dose administered, rate of

absorption and rate of

elimination.

(c) Time of administration, rate

of absorption and rate of

elimination.

(d) Route of administration, rate

of absorption and rate of

elimination.

65. Drug when administered at a

dose of 40 mg showed an initial

concentration of 0.5 µg/ml.

Given the half life of the drug to

be 2 hr, what is the total

clearance of the drug ?

(a) 27.68 l/hr.

(b) 29.48 l/hr.

(c) 25.48 l/hr.

(d) 29.87 l/hr.

66. Which of the following sentence

is incorrect ?

(a) Adipose tissue has a smaller

proportion of water

compared to a muscle tissue.

(b) The distribution volumes are

tend to be larger in neonates

than in adults.

(c) The apparent volume of

distribution for the drugs

having lower lipid solubility

is larger in elderly.

(d) The dosing interval is

calculated on the basis of

half-life of the drug.

67. Match the following :

LIST – I LIST – II

A. Average

drug

conc. at

steady-

state

1. 1

(1– eKEτ

)

B. Ac-

cumulat-

ion index

2.1

(1– eKaτ) (1– eKEτ)

C. Loading

dose 3.

1

(1– eKEτ

)

D. Loading

dose in

i.v.

4. FX0

ClTτ

Codes :

A B C D

(a) 3 4 1 2

(b) 4 3 1 2

(c) 4 3 2 1

(d) 3 1 4 2

27 (26 – A)

68. Ç·ÈæÔåê¤’ðëé’ðñÄð°’óÞÄåêÆ ŠÑðÓÑ–Ó ÊâÿåÜÈå Ñæ˜µåê¼å¾Áµð ?

1. ËÚÈåÁ·™˜µåâÿå ƒÊ–·ÔåïÁ™ÂÃ²ìåêÑ–Ó

2. ´µðëéÜÈðé¦ÿó ÇÈåÁµåÂÃ½˜µåâÿå ÕÄæÏÜÈåÁµåÑ–Ó

3. In vitro-in vivo ÜÈåßåÜÈåÒÊÒÁ·µå

ƒÁ·µåùÏ²ìåêÄå µåâÿåÑ–Ó

4. Õ×ðÓéÚÈå¹æ¼åÍ’å ÔåìæÇÈå˜µåâÿåÑ–Ó

5. ¼å’å¤ÜÈåÒ˜µå¼å ËÚÈåÁ·™ ÕÄæÏÜÈåÁµåÑ–Ó

(a) 1, 2, 3, 5

(b) 1, 2, 4, 5

(c) 1, 2, 5

(d) 1, 2, 3, 4, 5

69. † ’ðâÿå ™Äå ²ìåìæÔå Ôå˜µå¤˜µåâÿå ËÚÈåÁ·™˜µåâ– µð TDM ÜÈåë’å¾Ôæ˜™Áµð ?

(a) ÇÈðîÐ´µåÐ˜µóÞ

(b) Ôðê®ÊðëÑðñ®ÄåêÆ ôåê²µåê’æ˜™ÜÈåêÔå ´µåÐ µóÞ

(c) ƒÒ°Ê²ìåìæ°’ó˜µåâÿåê

(d) ƒÒ°ŠÇÝÑðÇÝ±’ó˜µåâÿåê

70. TDM ÄåÑ–Ó ÔåìæÁµå²™ µåâÿåÄåêÆ Õ×ðÓéÚÈå¹ð µæ˜™ ²ìåìæÔæ˜µå àÒ¼ð˜µðÁµåê’ðëâÿåäÑæ˜µåê¼å¾Áµð ?

(a) Åé´™’ð²ìåìæÁµå ¼å’åÛ¸

(b) MEC ²ìåêÄåêÆ ¼åÑêÇÝÁµå ÄåÒ¼å²µå

(c) ÜÝÀ²µåÜÝÀ½²ìåêÄåêÆ ¼åÑêÇÝÁµå ÄåÒ¼å²µå

(d) 5 ÅÕêÚÈå˜µåâÿå ÄåÒ¼å²µå

71. ’å ™Ôðê ƒÁ·µå¤ ƒ²ìåêêÚÈåÏÕ²µåêÔåÒÁ¿·µå

ËÚÈåÁ·™˜µåâÿå ÕÚÈå²ìåêÁµåÑ–Ó ÔåìæÁµå²™ µåâÿåÄåêÆ

²ìåìæÔå ÜÈæÒÁµåÐ¼ð²ìåêÑ–Ó ÜÈåÒ µåÐàÜÈåÑæ µåê¼å¾Áµð ?

(a) Õ¼å²µå¹ð²ìåìæÁµå ÄåÒ¼å²µå

(b) Õ¼å²µå¹ð µð ÔðëÁµåÑê

(c) ®ÐÇ·Èó ÜÈæÒÁµåÐ¼ð²ìåêÑ–Ó

(d) ÜÈåë’å¾ ÜÈæÒÁµåÐ¼ð²ìåêÑ–Ó

72. ´µðëéÜÈðé¦ÿó ÇÈåÁµåÂÃ½²ìåêÄåêÆ Å¸¤ÎêÜÈåêÔå

’ðâÿå’åÒ µå ƒÒ×å µåâÿåÄåêÆ ÜÈå²™ßðëÒÁ™ÜÝ.

ÇÈå°± – I ÇÈå°± – II

A. „“±Õ°-

¯æ“ÞÜÝ°

1. ²™éÄåÑó

¼ðëÒÁµå²µð µåâÿåê

B. Ç·ÈæÔåê¤’ðëé

’ðñÄð°’óÞ

2. ÊßåêÜÈåÑÁµå

ËÚÈåÁ·™ ¡“¼ðÞ

C. ²µðëé˜™²ìåê

“ÓÅ’åÑó ÜÝÀ½

3. ÕÜÈå¦¤Äð

D. ¡“¼ðÞ²ìåê

ÅÔå¤ßå¹ð

4. Á¿·µð²µåÇÝ±’ó

…Ò´µð’óÞ

Codes :

A B C D

(a) 1 3 4 2

(b) 3 4 2 1

(c) 4 3 1 2

(d) 2 4 3 1

27 (27 – A)

68. Which of the following are the

applications of pharmacokinetics ?

1. Drug development

2. Designing dosage regimen

3. In vitro-in vivo correlation

studies

4. Analytical measurement

5. Rational drug design

Codes :

(a) 1, 2, 3, 5

(b) 1, 2, 4, 5

(c) 1, 2, 5

(d) 1, 2, 3, 4, 5

69. TDM is suitable for which of the

following classes of drugs ?

(a) Prodrugs

(b) Drugs which are active

metabolite

(c) Antibiotics

(d) Antiepileptic

70. The samples are withdrawn for

analysis in TDM :

(a) Immediately after

administration

(b) After reaching the MEC

(c) After reaching steady state

(d) After 5 minutes

71. The collection of samples for the

drug with shorter half-life are

done in which concentration ?

(a) After distribution

(b) Before distribution

(c) Trough concentration

(d) Optimum concentration

72. Match the following factors that

determine the dosage regimen :

LIST – I LIST – II

A. Activity-

Toxicity

1. Renal

impairment

B. Pharma-

cokinetics

2. Multiple

drug

therapy

C. Clinical state

of patient

3. Excretion

D. Management

of therapy

4. Therapeutic

index

Codes :

A B C D

(a) 1 3 4 2

(b) 3 4 2 1

(c) 4 3 1 2

(d) 2 4 3 1

27 (28 – A)

73. † ’ðâÿå’åÒ´µåÒ¼ð “Ó²ìåê²µó „˜µåêÔå ËÚÈåÁ·™ µåâÿå

ÜÈåÒÁµåÊ·å¤ÁµåÑ–Ó ²µðëé˜™²ìåê ²µðéÜÈó ƒÄåêÆ

ÇÈå²™˜µåºÜÈåÑæ˜µåêÔåíúÁµåê.

(a) ßðÇÈæ°’ó Ôåìæ˜µå¤

(b) ÇÈåÑÍÄå²™ Ôåìæ˜µå¤

(c) ²™éÄåÑó Ôåìæ˜µå¤

(d) „’åêÏÑæ²µó Ôåìæ˜µå¤

74. Ñðëé´™Ò µó ´µðëéÜÈó …ÑÓÁµð TDMÄåêÆ

¼åÑêÇÈåÊðé’æÁµå²µð, ËÚÈåÁ·™²ìåê ÜÝÀ²µåÜÝÀ½²ìåêÄåêÆ

ÜÈæÁ·™ÜÈåÑê ËÚÈåÁ·™ µåâÿå ŠÚÈåê±

ƒÁ·µå¤ƒ²ìåêêÚÈåÏ˜µåâÿåÄåêÆ ’ðë µåÊðé’æ˜µåê¼å¾Áµð ?

(a) 2 „Á·µå¤ „²ìåêêÚÈåÏ

(b) 8 „Á·µå¤ „²ìåêêÚÈåÏ

(c) 5 „Á·µå¤ „²ìåêêÚÈåÏ

(d) 1 „Á·µå¤ „²ìåêêÚÈåÏ

75. Á™é›å¤’æÑ–’å ÔåêÁµåÏÜÈðéÔåÄð ÔåÏÜÈåÄåÔåíú ’ðâÿå µð

½â–ÜÝÁµå ËÚÈåÁ·™ µåâÿå TDM ÔðêéÑð ÇÈåÐ½’åëÑ

ÇÈå²™¹æÔåê Ê–é²µåê¼å¾Áµð.

(a) Ç·ÈðÅ¯æÎêÄó

(b) ´µðñ˜µæ“ÞÄó

(c) ’æÊæ¤Ôðêé¦ÿóÇÝÄó

(d) Ñ–Á¿·™²ìåêÒ

76. ’å ™Ôðê ÇÈåÐÔåìæ¸Áµå ÜÝé²µåÒ „ÑêÌûÏÕêÄó

ÜÈæÒÁµåÐ¼ð²ìåêê ’ðâÿå’åÒ´µå ²ìåìæÔå ËÚÈåÁ·™²ìåê

ÇÈðîÐé°éÄó ÊÒÁ·µå’å¼ð²ìåêÄåêÆ ’å ™Ôðê

Ôåìæ´µåÊßåêÁµåê ?

(a) ÇÈæÏ²µæÜÝ®ÔåìæÑó

(b) ´™’ðëÓÇ·ÈðÄæ’ó

(c) Ç·ÈåÔðëé°´µðñÄó

(d) Ç·ÈðÅ¯æÎêÄó

77. ËÚÈåÁ·™˜µåâÿå ÁµåêÊ¤âÿå’ð Ôåê¼åê¾ µåê¹æ¼åÍ’å

Õ×ðÓéÚÈå¹ð µæ˜™ ²ìåìæÔå ÕÁ·µæÄåÔåÄåêÆ

ÊâÿåÜÈåÑæ˜µåê¼å¾Áµð ?

(a) ßðëéÔðëé¨ÄåÜÈó ƒÜÈðé

(b) §Äó ÜÈð±ÇÈó µðÐûñ ’ðÕêÜÝ±ø

(c) CEDIA

(d) Ç·ÈåùîúÓ²µåÜÈðÄóÞ

78. ˜µåê²™ÅÁ·µæ¤²µåÁµå ËÚÈåÁ·™ Õ¼å²µå¹æ ÔåÏÔåÜÈðÀ µð

‡¼å¾Ôåê ÔåìæÁµå²™˜µåâÿåê ²ìåìæÔåíúÔðÒÁµå²µð †

’ðâÿå’åÒ µå ˜µåê¸ÔåÄåêÆ ßðëÒÁ™²µåêÔå

ËÚÈåÁ·™˜µåâÿåê

(a) ƒÁ·™’åÔæÁµå §®ê± “Ó²ìåê²µðÄóÞ

(b) ’å ™Ôðê²ìåìæÁµå §®ê± “Ó²ìåê²µðÄóÞ

(c) ƒÁ·™’å ÔåìæÑ–’åëÏÑ²µó ¼åë’å

(d) Êïßå¼ó Vd

27 (29 – A)

73. Race of the patient is taken into

consideration for drugs which are

cleared by

(a) Hepatic route

(b) Pulmonary route

(c) Renal route

(d) Ocular route

74. How many half-life of the drugs

should be given to attain the

steady state of the drug without

the loading dose to accesses the

TDM ?

(a) 2 half-life

(b) 8 half-life

(c) 5 half-life

(d) 1 half-life

75. Chronic alcoholism will affect

the TDM of which of the below

mentioned drugs ?

(a) Phenytoin

(b) Digoxin

(c) Carbamazepine

(d) Lithium

76. The low serum albumin

concentration may lower the

protein binding of which drug ?

(a) Paracetamol

(b) Diclofenac

(c) Famotidine

(d) Phenytoin

77. Which of the following method is

used to detect the abuse of drugs

and qualitative analysis ?

(a) Homogenous assay

(b) One step-dry chemistry

(c) CEDIA

(d) Fluorescence

78. Good candidates for targeted

drug delivery system are the

drugs with

(a) High total clearance

(b) Low total clearance

(c) High molecular weight

(d) Large Vd

27 (30 – A)

79. ¡“¼ðÞ²ìåê ‡ÜÈåê¾Ôæ²™ ÁµåïÚÝ±’ðëéÄåÔåíú, ½éÔåÐ¼ð²ìåê Ê˜µðš ƒ½éÔå Å˜µæ ÔåàÜÈåêÕ’ð ßæ˜µåë † ’ðâÿå ™Äå ÜÈåÒÊ·åÔåÁµå Ê˜µðš Å˜µæ ÔåàÜÈåêÕ’ð²ìåê ÅÔå¤ßå¹æ ²ìðëé¦Äð˜µð ÜÈåÒÊÒÁ·™ÜÝÁµð.

(a) ¡“¼ðÞ²ìåê ÇÈå²™¹æÔåê˜µåâÿå Ê˜µðš Ôåìæ¼åÐ

(b) ƒÄåÇÈðé“Û¼åÔæÁµå ÇÈåÐ½’åëÑ ÇÈå²™¹æÔåê˜µåâÿå Ê˜µðš Ôåìæ¼åÐ

(c) ¡“¼ðÞ²ìåê ÇÈå²™¹æÔåê µåâÿåê ßæ˜µåë ƒÄåÇÈðé“Û¼åÔæÁµå ÇÈåÐ½’åëÑ ÇÈå²™¹æÔåê˜µåâÿð²µå µå²µå Ê µð µåë

(d) ¡“¼ðÞ²ìåê ÇÈå²™¹æÔåê µåâÿå Ê˜µð µåë ƒÑÓ, ƒÄåÇÈðé“Û¼åÔæÁµå ÇÈåÐ½’åëÑ ÇÈå²™¹æÔåê˜µåâÿå Ê˜µð µåë ƒÑÓ

80. Š²µå µåê ÕÊ–·ÄåÆ ËÚÈåÁ·™ ‡¼åÉÄåÆ˜µåâÿå Ê˜µðš ƒÔåíú˜µåâÿå ÕØÚÈå± ˜µåê¸˜µåâ– µð ÜÈåÒÊÒÁ·™ÜÝÁµåÒ¼ð ÔðñÔðîé Ê²ìðëé†“ÖÔðéÑðÄóÞ ƒÁ·µåùÏ²ìåêÄå ˜µåâÿåÄåêÆ Äå µðÜÈåêÔæ˜µå ²ìåìæÔå ²ìåìæÔå „²ìåìæÔåê˜µåâÿåÄåêÆ ÇÈå²™˜µåºÜÈåÊðé’åê ?

1. Ôå’åÐÁµå ’ðâÿå˜™Äå ÇÈåÐÁµðé×å

2. Cmax (˜µå²™ÚÈå³ ÇÈæÓÜÈæÍ ËÚÈåÁ·µå ÇÈæÐÊÑÏ¼ð)

3. ¡“¼åÞ’å ÕÒ´µðëé

4. Tmax (˜µå²™ÚÈå³ ÇÈæÓÜÈæÍ ËÚÈåÁ·µå ÜÈæÒÁµåÐ¼ð²ìåêÄåêÆ ¼åÑêÇÈåíúÔåíúÁµå’ð” Êðé’æ˜µåêÔå ÜÈåÔåê²ìåê)

(a) 1 Ôåìæ¼åÐ

(b) 1 Ôåê¼åê¾ 2

(c) 1, 2 Ôåê¼åê¾ 3

(d) 1, 2 Ôåê¼åê¾ 4

81. ‡¼åÉÁµåÄæ ÅÔå¤ßå¹ð²ìåê ˜µåê²™˜µåâÿåê Ôåê¼åê¾

Á·µðùÏé²ìåê˜µåâÿåê ²ìåìæÔåíúÔðÒÁµå²µð

(a) ÜÈå²™²ìåìæÁµå ˜µåê¸, ÜÈå²™²ìåìæÁµå

ÇÈå²™Ôåìæ¸, ÜÈå’æÑ’ð” ƒÑÓ, ÜÈå²™²ìåìæÁµå

¼å²ìåìæ²™’æ Ôðôå¢

(b) ÜÈå²™²ìåìæÁµå ˜µåê¸, ÜÈå²™²ìåìæÁµå

ÇÈå²™Ôåìæ¸, ÜÈå²™²ìåìæÁµå ÜÈåÔåê²ìåê,

ÜÈå²™²ìåìæÁµå ¼å²ìåìæ²™’æ Ôðôå¢

(c) ÜÈå²™²ìåìæÁµå ˜µåê¸, ÜÈå²™²ìåìæÁµå

ÇÈå²™Ôåìæ¸ƒÑÓ, ÜÈå²™²ìåìæÁµå ÜÈåÔåê²ìåê,

ÜÈå²™²ìåìæÁµå ¼å²ìåìæ²™’æ Ôðôå¢

(d) ÔðêéÑ–Äå ²ìåìæÔåíúÁµåë ƒÑÓ

82. ÁµåÜÈæ¾Ôðé¦ê ŠÒÁµå²µð, Õ×ðéÚÈåÔæ˜™ †

’ðâÿå ™ÄåÁµå²µå Ôåìæà½²ìåêÄåêÆ §Áµå˜™ÜÈåêÔå Ñ–•–¼å

Ôå²µåÁ™ ƒÁ¿·µåÔæ Áµæ•Ñð,

(a) ´µðëéÜÈðé¦ÿó ÄåÔåêëÄð²ìåê ²µåôåÄð˜µð

ƒâÿåÔå ™ÜÝ’ðëÒ´µå ÕÁ·µæÄåÁµå Ôåìæà½.

(b) §ÒÁµåê ËÚÈåÁ·µå ×æÜÝ¾øé²ìåê ‡¼åÉÄåÆÁµå

Ôåìæ’ð¤°Ò˜µó ¼åÒ¼åÐ µåâÿå Ôåìæà½.

(c) ƒÁ·™’åï¼å ƒÁ¿·µåÔæ ’æÄåëÄåêÊÁµåÂÃ

Ôåìæà½


27 (31 – A)

79. Therapeutic Monitoring approach

refers to the management plan that

involves rigorous monitoring of

the intensity as well as incidence of

(a) Therapeutic effects only.

(b) Undesired adverse effets

only.

(c) Both Therapeutic effects and

undesired adverse effects.

(d) Neither Therapeutic effects

nor undesired adverse effects.

80. In vivo bioequivalence studies of

two different drug products with

respect to their characteristic

features, the parameters need to

be taken into consideration are

1. Area under the curve

2. Cmax (Maximum Plasma

drug conc.)

3. Therapeutic window

4. Tmax (Time required to reach

maximum Plasma drug conc.)

Select the correct codes :

(a) 1 only

(b) 1 and 2

(c) 1, 2 and 3

(d) 1, 2 and 4

81. The goals/objectives of the

production management are

(a) Right Quality, Right

Quantity, Not in time, Right

Manufacturing Cost.

(b) Right Quality, Right

Quantity, Right time, Right

Manufacturing Cost.

(c) Right Quality, Not in

Quantity, Right time, Right

Manufacturing Cost.

(d) None of the above.

82. Document is a written report or

record that provides information

especially of

(a) Procedure adopted for

formulation of dosage form.

(b) Marketing strategies of a

pharmaceutical product.

(c) An official or legal in

nature.


27 (32 – A)

83. ISO 9000 ÜÈå²µåº²ìåêê ŠÚÈåê±

ÔåìæÄå’å˜µåâÿåÄåêÆ §âÿå˜µðëÒ´™Áµð ?

(a) ŠÒ®ê ÇÈåÐÔåìæ¸

(b) ‹âÿåê ÇÈåÐÔåìæ¸

(c) §ÒÊ¼åê¾ ÇÈåÐÔåìæ¸

(d) ŒÁµåê ÇÈåÐÔåìæ¸

84. ÔðëÁµåÑ ¨ŠÒÇÝ ˜µåâÿåÄåêÆ ƒÔðêé²™’æÁµåÑ–Ó

ÇÈåÐ’å°ÜÝÁµå ÔåÚÈå¤

(a) ¦ëÄó 1973

(b) ¦ëÄó 1963

(c) ¦êÑðñ 1983


85. ¨ŠÒÇÝ ²ìåêÑ–Ó²µåêÔå ÇÈå²™˜µå Äð˜µåâÿåÄåêÆ †

’ðâÿå’åÒ µå ƒÄåêÜÈåë¡²ìåê ’ðâÿå µð ËÚÈåÁ·µå µåâÿåê

Ôåê¼åê¾ ÇÈåÐÜÈæÁµåÄå˜µåâÿå Å²ìåêÔåê˜µåâÿåÑ–Ó

ÜÈðé²™ÜÝ’ðëâÿåäÑæ ™Áµð.

(a) N

(b) X

(c) M


86. ŠÑÓ ÕÁ·µåÁµå ¼å²ìåìæ²™’æ ÕÁ·µæÄå˜µåâ– µð ÜÈåÒÊÒÁ·™ÜÝÁµå ÔåìæÜÈå±²µó Ç·ÈæÔåêê¤Ñæ ²™’æ µåê¤ µåâÿåÄåêÆ † ’ðâÿå ™ÄåÔå²µåê ÜÝÁµåÂÃÇÈå ™ÜÝ Áµåï ·µåÇÈå ™ÜÈå¼å’å”ÁµåêÂ.

(a) ’åÒÇÈåÅ²ìåê ÔåÏÔåÜÈæÀÇÈå’å ÅÁµð¤é×å’å²µåê

(b) ‡¼æÉÁµåÄð Ôåê¼åê¾ ˜µåê¸Ôåê®± Å²ìåêÒ¼åÐ¸Áµå Ôåêê•ÏÜÈåÀ²µåê

(c) Ôåìæ’ð¤°Ò˜µó Ôåêê•ÏÜÈåÀ²µåê


87. ÇÈæÐÜÈóÇÈð“±Ôó ÇÈðîÐéÜÈðÜÈó ÔæÏÑ–´µðé×åÄó ŠÒÁµå²µð,

(a) ¼å²ìåìæ²™’æ ÇÈåÐ“Ð²ìðê µåâÿåê ÜÝÀ²µåÔæ˜™Ôð ŠÒÁµåê ÇÈå²™ µåºÜÈåÑÉ®±Ò¼åßå ÇÈåÐ½ÚÈæ±ÇÝ¼å ‡¼åÉÄåÆ˜µåâ– µð ÔæÏÑ–´µðé×åÅÆÄå „²ìðê”.

(b) ÇÈåÐ“Ð²ìðê²ìåêÄåêÆ Ôæº¦Ï ‡ÁµðÂé×å’æ”˜™ ¦ÿæ²™ µð ¼å²µåêÔå ÔðëÁµåÑê, ÔæÏÑ–´µðé×åÄó ÇÈðîÐé ðëé’æÑó ŠÒÁµåê ’å²µð²ìåêÑæ˜µåêÔå §ÒÁµåê ÇÈæÐ²ìðëé˜™’å ²ìðëé¦Äð²ìåêÄåêÆ ÅÔå¤àÜÈåÑæ˜µåêÔå ÇÈåÐ“Ð²ìðê (ƒßå¤¼æ ÇÈåÐ²ìðëé˜µå µåâÿåê ÇÈåî¸¤ µðëÒ µå ÄåÒ¼å²µå …ÁµåÄåêÆ ’ðñ˜µðëâÿåäÑæ˜µåêÔåíúÁµåê)

(c) “Ð°’åÑó ÇÈðîÐéÜÈðÜÝÒ µó ßåÒ¼å˜µåâÿåÄåêÆ ÇÈåÐÁ¿·µåÔåê ßåÒ¼åÁµåÑ–Ó²ìðê ‡ÜÈåê¾Ôæ²™ Ôåìæ´µåêÔåíúÁµåê Ôåê¼åê¾ ÇÈåÐÜÈåê¾¼å ‡¼åÉÄåÆÁµå ÇÈå²™é’åÛ¹ð


27 (33 – A)

83. ISO 9000 series consists of

(a) Eight Standard

(b) Seven Standard

(c) Nine Standard

(d) Five Standard

84. The first GMPs were published in

America on

(a) June 1973

(b) June 1963

(c) July 1983

(d) None of the above

85. The GMP considerations are

included in Drugs and Cosmetics

rules under schedule

(a) N

(b) X

(c) M


86. Master formula records relating

to all manufacturing procedures

shall be prepared and endorsed by

(a) Managing Director of the

company.

(b) Head of the production and

Quality Control.

(c) Head of the Marketing.


87. Prospective process validation

means

(a) Validation option for

established products whose

manufacturing processes are

considered stable.

(b) Validation process, an

experimental plan called the

validation protocol is executed

(following completion of the

qualification trials) before the

process is put into commercial

use.

(c) In process monitoring of

critical processing steps end

product testing of current

production.


27 (34 – A)

88. Êïßå¼ó µæ¼åÐÁµå ÇÈðé²µðÒ ð²µåÑóÞ ŠÒÁµå²µðé,

(a) ÜÝÁµåÂÃ˜µðëÒ´µå µðëéÜÈðé¦ÿó ²µåëÇÈåÁµå §ÒÁµåê Á·µæ²µå’åÁµåÑ–Ó 25 ml ƒÁ¿·µåÔæ ƒÁµå“”Ò¼å ßð¡¢Äå ƒâÿå¼ð²ìåêÑ–Ó²µåêÔå ÜÈð±²µðñÑó ÁµæÐÔå .

(b) ÜÝÁµåÂÃ˜µðëÒ´µå µðëéÜÈðé¦ÿó ²µåëÇÈåÁµå §ÒÁµåê Á·µæ²µå’åÁµåÑ–Ó 50 ml ƒÁ¿·µåÔæ ƒÁµå“”Ò¼å ßð¡¢Äå ƒâÿå¼ð²ìåêÑ–Ó²µåêÔå ÜÈð±²µðñÑó ÁµæÐÔå .

(c) ÜÝÁµåÂÃ˜µðëÒ´µå µðëéÜÈðé¦ÿó ²µåëÇÈåÁµå §ÒÁµåê Á·µæ²µå’åÁµåÑ–Ó, 100 ml ƒÁ¿·µåÔæ ƒÁµå“”Ò¼å ßð¡¢Äå ƒâÿå¼ð ²ìåêÑ–Ó²µåêÔå ÜÈð±²µðñÑó ÁµæÐÔå¸.


89. ANDA ŠÒÁµå²µð,

(a) ƒÊó ÄæÔåê¤Ñó ÄåëÏ µåÐ µó ƒÇÝÓ’ðé×åÄó

(b) ƒÊ–ÐÔðé ð´µó ÄåëÏ´µåÐ˜µó ƒÇÝÓ’ðé×åÄó

(c) ƒÊ–ÐÔðé ð´µó ÄæÔðÑó ´µåÐ˜µó ƒÇÝÓ’ðé×åÄó


90. ÜÈð±²µðñÑó ÜÈðëéÜÈåêÕ’ð µð, ÔðêÒÊðÐéÄó Ç·ÝÑ±²µó Õêé´™²ìåìæÁµå ²µåÒÁ·µåùÐ˜µæ¼åÐÔåíú ŠÚÝ±²µåÊðé’åê ?

(a) 0.44 – 0.48 µm

(b) 0.20 – 0.22 µm

(c) 0.60 – 0.68 µm

(d) 0.80 – 0.88 µm

91. ÜÈð±²µðñÑó ÜÝÁµåÂÃ¼ð˜µð ÜÈåÑßð Ôåìæ´µåÑæÁµå Åé²™Äå ˜µåê¸Ôåê®±Ôåíú ¦ÿðñÕ’å ×åêÁµåÂÃ¼ð²ìåê ÁµåïÚÝ±ÎêÒÁµå ²ìåìæÔå ²™é½ …²µåÊðé’åê ?

(a) 10 CFUs/100 ml ˜™Ò¼å ßðôæ¢˜™²µå-Êæ²µåÁµåê

(b) 20 CFUs/100 ml ˜™Ò¼å ßðôæ¢˜™²µå-Êæ²µåÁµåê

(c) 100 CFUs/100 ml ˜™Ò¼å ßðôæ¢˜™²µå-Êæ²µåÁµåê

(d) 50 CFUs/100 ml ˜™Ò¼å ßðôæ¢˜™²µå-Êæ²µåÁµåê

92. SUPAC ŠÒÊêÁµå²µå ÕÜÈå¾üï¼å ²µåëÇÈå

(a) ÜÈæ±ûÏÒ´µå µó¤ ƒÇÈó ƒÒ µó ÇÈðîéÜÈó± ƒÇÈåîÐÔåÑó ôðéÒ¦ÿó

(b) ÜÈð”éÑó ƒÇÈó ƒÒ´µó ÇÝÐ ƒÇÈåîÐÔåÑó ôðéÒ¦ÿó

(c) ÜÈð”éÑó ƒÇÈó ƒÒ´µó ÇÈðîéÜÈó± ƒÇÈåîÐÔåÑó ôðéÒ¦ÿó


93. Áµðë´µå¶ µæ¼åÐÁµå …Ò¦ÿð’åÛÄó˜µåâÿåÄåêÆ ƒÒ½Ôåê Á·µæ²µå’åÁµåÑ–Ó _____ ˜µåÒ ð˜µåâÿðëâÿå˜µæ ™ ¼åêÒÊ–ÜÝ´µåêÔåíúÁµåê ƒ˜µå¼åÏ …ÑÓÔæÁµåÑ–Ó, ²ìåìæÔåíúÁµðé Ôðêñ’ðëÐéÊ–²ìåêÑó ÇÈåÐÁµåëÚÈå Á™ÒÁµå ƒÁ·™’å Ôåê®±Áµå ÇÈðñ²µðëé¦ÿðÅ’ó ÔåÜÈåê¾ ²µåëÇÈåíú µðëâÿåäÊßåêÁµæ˜™Áµð.

(a) 56

(b) 72

(c) 48

(d) 86

27 (35 – A)

88. Large-volume parenterals means

(a) Sterile solution with volume

of 25 ml or more in one

container of the finished

dosage form.

(b) Sterile solution with volume



dosage form.

(c) Sterile solution with volume



dosage form.


89. ANDA means

(a) Abnormal New Drug

Application

(b) Abbrivated New Drug

Application

(c) Abbrivated Novel Drug

Application


90. The pore size of the membrane

filter media for sterile filtration

are

(a) 0.44 – 0.48 µm

(b) 0.20 – 0.22 µm

(c) 0.60 – 0.68 µm

(d) 0.80 – 0.88 µm

91. Water Quality in terms of

biological purity for sterile

preparation suggested of

(a) Not more than 10 CFUs/100 ml

(b) Not more than 20 CFUs/100 ml

(c) Not more than 100 CFUs/100 ml

(d) Not more than 50 CFUs/100 ml

92. SUPAC means

(a) Standard-up and Post

Approval Change

(b) Scale-up and Pre Approval

Change

(c) Scale-up and Post Approval

Change


93. Bulk injections are usually

required to be filled into final

container within ______ hours,

otherwise any microbial

contamination could result in

high level of pyrogenic materials.

(a) 56

(b) 72

(c) 48

(d) 86

27 (36 – A)

94. Á™é›æ¤ÔåÁ·™ ƒÁ·µåùÏ²ìåêÄå µåâ– µæ˜™ ÜÝÀ²µåÔåê®±Áµå ÜÈåÒ µåÐßå ÜÝÀ½ ²ìåìæÔå ²™é½ …²µåÊðé’åê ?

(a) 25° ± 2 °C ²µåÑ–Ó 60% RH ±

5% ÄðëÒÁ™ µð ’åÅÚÈå± 12

½Ò˜µåâÿåê˜µåâÿåê.

(b) 40° ± 2 °C ²µåÑ–Ó 75% RH ±

5% ÄðëÒÁ™ µð ’åÅÚÈå± 6 ½Ò˜µåâÿåê µåâÿåê.

(c) 25° ± 2 °C ²µåÑ–Ó 60% RH ±

5% ÄðëÒÁ™ µð ’åÅÚÈå± 6 ½Ò˜µåâÿåê µåâÿåê.


95. ‡¼æÉÁµå’å¼ð ŠÄåêÆÔåíúÁµåÄåêÆ àé µð ÔæÏ•ÿæÏÅÜÈåÑæ˜µåêÔåíúÁµåê ?

(a) ÇÈå µðÁµåê’ðëâÿåäÑæÁµå ‡¼åÉÄåÆÁµå ’æÖÒ®Ò

(b) output ÅÒÁµå input ˜µð …²µåêÔå ƒÄåêÇÈæ¼å

(c) ÊâÿåÜÝ’ðëâÿåäÑæÁµå ’åôæ¢ ÜÈæÔåê˜™Ð˜µåâÿå Ôðë¼å¾


96. Åé²™Äå Ôå ™¤é’å²µå¸Áµå ÇÈåÐ’æ²µå, IVÄðé Ôåê®± ŠÒÁµå²µð,

(a) ÊæÕ²ìåê Åé²µåê ƒÁ¿·µåÔæ ’åôæ¢ Åé²µåê

(b) ×åêÁ™ÂÃé’å²™ÜÝÁµå Åé²µåê (“Ð°’åÑó ÊæÏôó Êâÿå’ð˜µð ‡ÇÈå²ìðëé˜™ÜÈåêÔå USP)

(c) ƒÒ½ÔåêÔæ˜™ ¦ÿæÑ–ÜÝ ¼ðëâÿð²ìåêÑê ßæ˜µåë ÇÈðé²µðÒ ð²µåÑó ‹²™²ìåìæ˜µåâÿåÑ–Ó Ç·ÈæÔåêê¤Ñðé×åÄå˜µð (WFI, USP) ÊâÿåÜÈåêÔå FDA Åé²µåê

(d) ’åê´™²ìåêêÔå Åé²µåê (Äå µå²µåÁµå Åé²µåê)

97. ²™ÔåÜÈó¤ ƒÜÈæÍÜÝÜÈó (R.O.) ‡ÇÈåôæ²µå˜µåâÿåê (a) ÊæÏ“±é²™²ìåìæ Ôåê¼åê¾ ÇÈðñ²µðëé¦ÿðÅ’ó

ÔåÜÈåê¾ µåâÿåÄåêÆ Ôåìæ¼åÐ ¼ð µðÁµåê ßæ’åê¼å¾Ôð. (b) ’å²µå˜™Áµå ÑÔå¸ µåâÿåê Ôåê¼åê¾

ÇÈæ°¤’åêÏÑðé®˜µåâÿåÄåêÆ, ÊæÏ“±é²™²ìåìæ ßæ˜µåë ÇÈðñ²µðëé¦ÿðÅ’ó ÔåÜÈåê¾ µåâÿåÄåêÆ ¼ð˜µðÁµåê ßæ’åê¼å¾Ôð.

(c) ’å²µå˜µåÁ™²µåêÔå ÑÔå ˜µåâÿåÄåêÆ Ôåìæ¼åÐ ¼ð˜µðÁµåêßæ’åê¼å¾Ôð.


98. ƒÑæ±øÇ·ÝÑ±²µó µåâÿåê ’ðâÿå’åÒ´µå ˜µæ¼åÐÁµå ’å¸ µåâÿåÄåêÆ ¼ð˜µðÁµåê ßæ’åê¼å¾Ôð.

(a) 0.001 – 0.01 µm ÔæÏÇÝ¾

(b) 0.044 – 0.22 µm ÔæÏÇÝ¾ (c) 0.001 – 0.01 mm ÔæÏÇÝ¾ (d) 0.044 – 0.22 mm ÔæÏÇÝ¾

99. HEPA ÜÈðëéÜÈåê˜µå ŠÒÊêÁµå²µå ÕÜÈå¾üï¼å ²µåëÇÈå (a) ßðñ ŠÇ·Èð“±Ôó ÇÈæ°¤’åêÏÑðé¯ó ‹²µó

Ç·ÝÑ±²µóÞ (b) ßðñ ŠÇ·ÝØ²ìðêÅÞ ÇÈæ°¤’åêÏÑðé¯ó

‹²µó Ç·ÝÑ±²µóÞ (c) ßðÕ ŠÇ·ÝØ²ìðêÅÞ ÇÈæ°¤’åêÏÑðé¯ó

‹²µó Ç·ÝÑ±²µóÞ (d) ÔðêéÑ–Äå ²ìåìæÔåíúÁµåë ƒÑÓ

100. CFU/g ƒÁ¿·µåÔæ ml ÄåÑ–Ó ²ìðëéÅÔåìæ˜µå¤Ôæ˜™ Åé´µåÑæ˜µåêÔå ÜÈå±²µðñÑó ƒÑÓÁµå, ƒÒ½ÔåêÔæ˜™ ÜÝÁµåÂÃ µ ðëÒ µå ´µðëéÜÈðé¦ÿó ÄåÑ–Ó ƒÄåêÔåê½ÜÈåÑæÁµå ÊæÏ“±é²™²ìåìæ˜µåâÿå ÜÈåÒ•ÿðÏ²ìåê Õê½.

(a) 150

(b) 200

(c) 100

(d) 300

27 (37 – A)

94. Stability storage condition for

long term studies

(a) At 25° ± 2 °C with 60% RH

± 5% with at least 12

months.

(b) At 40° ± 2 °C and 75% RH

± 5% with at least 6 months.

(c) At 25° ± 2 °C with 60% RH

± 5% with at least 6 months.


95. Productivity defined as

(a) The Quantum of product

obtained.

(b) Ratio of output to input.

(c) The amount of raw materials

consumed.


96. As per water classifications,

Level IV means

(a) Well water/Raw water

(b) Purified water (USP used

for critical batch

application)

(c) FDA water for final rinse

and formulation (WFI, USP)

in parenteral areas.

(d) Drinking water (city water)

97. Reverse osmosis (R.O)

treatments will remove

(a) Only bacteria and pyrogenic

materials.

(b) Dissolved salts and also

particulates bacteria and

pyrogenic materials.

(c) Only insoluble salts.


98. Ultrafilters remove the particle

size

(a) Range 0.001 – 0.01 µm

(b) Range 0.044 – 0.22 µm

(c) Range 0.001 – 0.01 mm

(d) Range 0.044 – 0.22 mm

99. HEPA filter means

(a) High effective particulate air

filters.

(b) High efficiency particulate

air filters.

(c) Heavy efficiency particulate

air filters.


100. The bacterial count limits for

non-sterile finished dosage form

administered through vaginal

route in CFU/g or ml.

(a) 150

(b) 200

(c) 100

(d) 300

¡¼åê¾ Ê²µåßå’æ”˜™ ÜÈåÀâÿåSPACE FOR ROUGH WORK

27 (38 - A)

¡¼åê¾ Ê²µåßå’æ”˜™ ÜÈåÀâÿåSPACE FOR ROUGH WORK

(39 - A) 27

ÔåÚÈå¤Äó ’ðëé µó

† ÇÈåÐ×ðÆÇÈåíúÜÝ¾’ð²ìåêÄåêÆ ¼ð²µð²ìåêêÔåÒ¼ð ÅÔåê˜µð ½â–ÜÈåêÔåÔå²µð˜µåë …ÁµåÄåêÆ ¼ð²µð²ìåê’åë´µåÁµåê.

ÇÈåÐ×ðÆÇÈåíúÜÝ¾’ðÅÁ™¤ÚÈå± ÇÈå½Ð’ð

(ÇÈå½Ð’ð-II)úúúúú

µå²™ÚÈå³ ÜÈåÔåê²ìåê ‘ 2 µåÒ ð µåâÿåê µå²™ÚÈå³ ƒÒ’å µåâÿåê ‘ 200

DA

’åÐÔåê ÜÈåÒ•ÿðÏ :ÕÚÈå²ìåê ÜÈåÒ’ðé¼å :27

ÜÈåëôåÄð˜µåâÿåê1. ÇÈå²™é’ðÛ ÇÈæÐ²µåÒÊ·å µðëÒ µå ¼å’åÛ¸Ôðé õ.ŠÒ.„²µó. ‡¼å¾²µå ßæâÿð²ìåêÑ–Ó ÇÈåÐ×ðÆ ÇÈå½Ð’ð ×ðÐéº²ìåêÄåêÆ µåê²µåê¼åê Ôåìæ µåêÔå

ÔðëÁµåÑê, † ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð²ìåêÑ–Ó ÔåêêÁ™Ð¼åÔæ µåÁµå ƒÁ¿·µåÔæ ßå²™Á™²µåêÔå ƒÁ¿·µåÔæ ²ìåìæÔåíúÁµðé ÇÈåíú® …ÑÓÁ™²µåêÔå ƒÁ¿·µåÔæÔåêêÁ™Ð¼åÔæ µåÁµå ÇÈåÐ×ðÆ µåâÿåê …¼æÏÁ™ §âÿå µðëÒ ™ÑÓÔðÒÊêÁµåÄåêÆ ÅéÔåíú ÇÈå²™é“ÛÜÈå¼å’å”ÁµåêÂ. ÔðêéÑ–Äå ²ìåìæÔåíúÁµðé ÁµðëéÚÈå’åÒ µåêÊÒÁµåÑ–Ó ƒÁµåÄåêÆ àÒ½²µåê ™ÜÝ ÑÊ·åùÏÕ²µåêÔå ×ðÐéº²ìåê ÇÈå²™ÇÈåî¸¤ÔæÁµå Êðé²µð ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð²ìåêÄåêÆ ÇÈå µð²ìåê¼å’å”ÁµåêÂ.

2. ƒÊ·åùÏÁ¿·™¤²ìåêê ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð²ìåê ÔåÚÈå¤Äó ’ðëé µó A, B, C ƒÁ¿·µåÔæ D, ƒÄåêÆ Ôåê¼åê¾ ÄðëéÒÁµåº ÜÈåÒ•ÿðÏ²ìåêÄåêÆ OMR

‡¼å¾²µå ÇÈå½Ð’ð²ìåêÑ–Ó ƒÁµå’æ” ™ §Áµå ™ÜÈåÑæ ™²µåêÔå ÜÈåÀâÿåÁµåÑ–Ó Ê²µðÁµåê ÜÈåÒ’ðé¼å (ŠÄó ’ðëé µó) µðëâ–ÜÈåÊðé’åê. ßæ µåëÅ˜µåÁ™¼å ÜÈåÀâÿåÁµåÑ–Ó ¼æÔåíú Ôåê¼åê¾ ÜÈåÒÕé’åÛ’å²µåê ÜÈåà Ôåìæ´™²µåêÔåíúÁµåÄåêÆ •¡¼å ÇÈå´™ÜÝ’ðëâÿåäÊðé’åê. õ.ŠÒ.„²µó.ßæâÿð²ìåêÑ–Ó ½â–ÜÝ²µåêÔå ²ìåìæÔåíúÁµðé Ôåìæà½²ìåêÄåêÆ Ê·å½¤ Ôåìæ µåêÔåíúÁµåê/ŠÄó ’ðëé µó Ôåìæ µåêÔåíúÁµåê ƒÊ·åùÏÁ¿·™¤ µåâÿå¦ÔæÊæÂ²™²ìåìæ ™²µåê¼å¾Áµð. §ÒÁµåê Ôðéâÿð Ê·å½¤ Ôåìæ µåÁ™ÁµåÂÑ–Ó/¼åÇÝÉÁµåÂÑ–Ó ƒÒ¼åßå õ.ŠÒ.„²µó. ‡¼å¾²µå ßæâÿð²ìåêÄåêÆ½²µåÜÈå”²™ÜÈåÑæ µåêÔåíúÁµåê.

3. ÇÈå’å”ÁµåÑ–Ó §Áµå ™ÜÝ²µåêÔå ôò’åÁµåÑðÓé ÅÔåêÍ ÄðëéÒÁµåº ÜÈåÒ•ÿðÏ²ìåêÄåêÆÄåÔåêëÁ™ÜÈåÊðé’åê. ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð²ìåêÑ–Ó Êðé²µð ‹ÄåÄåëÆ Ê²µð²ìåêÊæ²µåÁµåê.

4. † ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð 100 ÇÈåÐ×ðÆ µåâÿåÄåêÆ §âÿå µðëÒ ™²µåê¼å¾Áµð. ÇÈåÐ½²ìðëÒÁµåê ÇÈåÐ×ðÆ²ìåêê 4 ‡¼å¾²µå µåâÿåÄåêÆ §âÿå µðëÒ ™²µåê¼å¾Áµð.ÅéÔåíú ‡¼å¾²µå ÇÈå½Ð’ð²ìåêÑ–Ó µåê²µåê¼åê Ôåìæ µåÊðé’ðÒÁ™ÅÜÈåêÔå ‡¼å¾²µåÔåÄåêÆ „²ìðê” Ôåìæ ™’ðëâ–ä. §ÒÁµåê Ôðéâÿð ƒÑ–Ó §ÒÁµå“”Ò¼åßðôåê¢ ÜÈå²™²ìåìæÁµå ‡¼å¾²µå µåâ–Ôð²ìðêÒÁµåê ÅéÔåíú Ê·æÕÜÝÁµå²µð ƒ¼åêÏ¼å¾ÔåêÔðÅÜÈåêÔå ‡¼å¾²µå’ð” µåê²µåê¼åê Ôåìæ ™. ‹Äðé „Áµå²µåëÇÈåÐ½ ÇÈåÐ×ðÆ µð ÅéÔåíú ’ðéÔåÑ §ÒÁµåê ‡¼å¾²µåÔåÄåêÆ Ôåìæ¼åÐ „²ìðê” Ôåìæ µåÊðé’åê.

5. ŠÑæÓ ‡¼å¾²µå µåâÿåÄåêÆ ÅÔåê µð §Áµå ™ÜÈåÑæ ™²µåêÔå ÇÈåÐ¼ðÏé’å ‡¼å¾²µå ÇÈå½Ð’ð²ìåêÑ–ÓÓ (OMR Sheet) ’ðéÔåÑ ’åÇÈåíþÉ ƒÁ¿·µåÔæ ÅéÑ–×æÎê²ìåê ÊæÑóÇÈæÎêÒ¯ó ÇÈðÅÆÄåÑ–Ó Ôåìæ¼åÐ µåê²µåê¼åê Ôåìæ µåÊðé’åê. ‡¼å¾²µå ÇÈå½Ð’ð ßæâÿð²ìåêÑ–ÓÄå ÜÈåëôåÄð µåâÿåÄåêÆ

µåÔåêÅÜÈåêÔåíúÁµåê.6. ŠÑæÓ ÇÈåÐ×ðÆ µåâ– µð ÜÈåÔåìæÄå ƒÒ’å µåâÿåê. ŠÑæÓ ÇÈåÐ×ðÆ µåâ– µåë ‡¼å¾²™ÜÝ²™.7. ¡¼åê¾ ’ðÑÜÈå’æ”˜™ ßæâÿð˜µåâÿåÄåêÆ ÇÈåÐ×ðÆ ÇÈåíúÜÝ¾’ð²ìåê ’ðëÄð²ìåêÑ–Ó ÜÈðé²™ÜÈåÑæ˜™Áµð. ÇÈåÐ×ðÆÇÈåíúÜÝ¾’ð²ìåê …ÄåêÆâ–Áµå ²ìåìæÔå

Ê·æ µåÁµåÑ–Ó²ìåêë ÅéÔåíú ²ìåìæÔå ²™é½²ìåê µåê²µåê¼åÄåêÆ Ôåìæ µå¼å’å”ÁµåÂÑÓ.8. ÇÈå²™é’ðÛ²ìåê Ôåêê’æ¾²ìåêÔåÄåêÆ ÜÈåë¡ÜÈåêÔå ƒÒ½Ôåê µåÒ ð Êæ²™ÜÝÁµå ¼å’åÛ¸Ôðé ‡¼å¾²µå ÇÈå½Ð’ð²ìåê ßæâÿð²ìåêÑ–Ó …ÄæÆÔåíúÁµðé

µåê²µåê¼åêÔåìæ µåêÔåíúÁµåÄåêÆ ÅÑ–ÓÜÈåÊðé’åê. ÜÈåÒÕé’åÛ’å²µåê ÊÒÁµåê ÅÔåêÍÑ–Ó²µåêÔå ‡¼å¾²µå ÇÈå½Ð’ð²ìåê ßæâÿð²ìåêÄåêÆ ¼åÔåêÍ Ôå×å’ð”¼ð µðÁµåê’ðëÒ µåê Ñð’å”’ð” ¼ð µðÁµåê’ðëâÿåêäÔåÔå²µð µåë ÅÔåêÍ ÅÔåêÍ „ÜÈåÄåÁµåÑ–Ó²ìðêé ’åêâ–½²µå¼å’å”ÁµåêÂ.

9. ÇÈåÐ×ðÆ µåâÿåê ’åÄåÆ µå Ôåê¼åê¾ „Ò µåÓ Ê·æÚÈð²ìåêÑ–Ó²µåê¼å¾Ôð. ’åÄåÆ µå ÇÈåÐ×ðÆ µåâÿåÑ–Ó ÜÈåÒÁµðéßå ‡Ò¯æÁµå²µð, Áµå²ìåêÕ®ê± „Ò µåÓ Ê·æÚÈð²ìåêÇÈåÐ×ðÆ˜µåâÿåÄåêÆ ˜µåÔåêÅÜÈåêÔåíúÁµåê. ÇÈåÐ×ðÆ ÇÈå½Ð’ð²ìåê ÇÈåÐ×ðÆ˜µåâÿåÑ–Ó ²ìåìæÔåíúÁµðé ˜µðëÒÁµåÑ˜µåâ–ÁµåÂ²µåë „Ò˜µåÓÊ·æÚÈð²ìåê ÇÈåÐ×ðÆ˜µåâÿðéƒÒ½ÔåêÔæ ™²µåê¼å¾Ôð.

ÄðëÒÁµåº ÜÈåÒ•ÿðÏ

²ìåìæÔåíúÁµðé ²™é½²ìåê ÔðëÊðñÑó Ç·ÈðùîéÄó, ’æÏÑó ’åêÏÑðé®²µó Ôåê¼åê¾ …¼å²µð ²™é½²ìåê ŠÑð’æ±øÅ’ó/’åÔåêêÏÅ’åðéÚÈåÄóÜÈæÁ·µåÄå µåâÿåê …¼æÏÁ™ µåâÿåÄåêÆ ÇÈå²™é’æÛ ’ðéÒÁµåÐÁµå „Ôå²µå Áµðëâÿå µð ¼å²µåêÔåíúÁµåÄåêÆ ÅÚÈðéÁ·™ÜÝÁµð.

Note : English version of the instructions is printed on the front cover of this booklet.27-A

question booklet specific paperkpsc.kar.nic.in/27.pdf · 27 (3 – a) 1. in a polarimeter a...

Documents